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Abbreviations
a

expression of significance level/ probability of a Type 1 error

a'

Anderson Darling's test statistic for goodness of fit

ADP

adenosine diphosphate

ALP

alkaline phosphatase

ALT

alanine aminotransferase

AMP

2-amino-2-methy 1-1 -propanol

AST

aspartate aminotransferase

ATP

adenosine triphosphate

BA

analytical bias

BCP

bromocresol purple

CUE

cholesterol esterase

Clio

cholesterol oxidase

CK

creatine kinase

CLJA’ 88

The American Clinical Laboratory Improvement Act of 1988

CT.Sl

Clinical and L.aboratory Standards Institute,

CPA

Clinical Pathology Accreditation (UK.) L.td.

CSF

cerebrospinal fluid

CUH

Cork University Hospital

cv

coefficient of variation

CVA

analytical coefficient of variation

CVG

between subject coefficient of variation

CVl

vvithin-subject coefficient of variation

CVT

total coefficient of variation

d

variance or deviation

df.

density function

Dm ax

Kolmogorov-Smirnov's test statistic

AE

change in electromotive force

EPTRV

The Expert Panel on Theory of Reference Values

EQAS

External Quality Assurance Schemes

F

Fraction

F- DAOS

chromogen system used in Olympus 1IDL assay

111

Fit

iterations fraction

GP

general practitioner

G6P

glucose-6-phosphate

GGT

gamma glutamyltransferase
coefficient of kiirtosis

GK

glycerol kinase

GLDH

glutamate-dehydrogenase

GPO

glycerol phosphate oxidase

gs

coefficient of skewness

IlbAlc

Haemoglobin Ale

IlCL

hydrochloric acid

IlDL

high density lipoprotein cholesterol

HK

hexokinase

i

i = 1,.......N

IFCC

Committee on Standards of the International Federation of Clinical Chemistry

II

index of individuality

IQR

interquartile range

ISF

ion specific electrode

ISO

The International Organisation for Standardisation (ISO)

LOII

lactate dehydrogenase

LDL

low density lipoprotein cholesterol

In

natural log

MCV

mean cell volume

MDII

malate dehydrogenase

NAD

nicotinamide adenine dinucleotide, reduced form

NADU

oxidised form of NAD

NADP

nicotinamide adenine dinucleotide phosphate, reduced form

NADPII

oxidised form of NADP

NCCLS

The National Committee for Clinical Laboratory Standards

NII4t

ammonia

NIIANFS

National Health and Nutrition Examination Survey

NIST

National Institute for Standards and Technology

NORIP

Nordic Reference Interval Project

IV

P-value

probability of observing a sample as extreme when the null hypothesis is true

pNP

para-nitrophenol

pNPP

para-nitropheno-phosphate

POD
PI'

peroxidase

RIW

Reference Interval Width

RMSE

root mean square error

V
/ .

sum of

SD

Standard Deviation

SDA

analytical standard deviation

SDI

vvithin-subject biological variation

SDl'

total variation

SE

standard error

ASEc

Critical Systematic Firror

I'E

Total error

TEa

total error allowable

iprz

2,4,6- Tri [2-pyridylJ-5-triazine

VIi)L

very low density lipoprotein cholesterol

vvi

cumulative Craussian distribution function

c

distribution

yi

modified logarithmic function yi = ln(x 1 + c),

z-data

probability that change is significant

/-scores

standard normal deviates,

Proficiency resting

1.0 Abstract
The objectives of this project were:
i.

To establish adult reference ranges for routine chemistries quoted in the
Clinical Biochemistry Department, Cork University Plospital (CUH), by using
samples from blood donors at the local blood bank. 120 samples of blood from
male blood donors and 120 samples from female blood donors were collected
from the Irish Blood Transfusion Service (Cork). These samples were
analysed for 21 routine chemistry analytes, using non-parametric statistics.

ii.

To study the statistics of nineteen routine chemistries of the adult population
served by the laboratory over a one- month period. Results were collected for
each of the age groups 18 to 45 years, 46 to 70 years, and over 70 years.
Weekday daily patient means were studied. To improve the significance of the
intervals, each age-group was further divided up by sex and by origin of
sample, CjP surgery or hospital. These means were then subjected to
parametric reference interval investigations.

iii.

To investigate the quality of the results of the nineteen analytes from the CUM
Biochemistry Department. Reference intervals are given a great deal of truth
by users and analyte performance may not warrant such faith. Therefore, a
study of quality specifications based on biological variation for all 19 analytes
was undertaken.

Conclusions
This project has shown that establishing an appropriate reference range is a very
difficult task.
i.

Analysis of samples from healthy individuals who had volunteered to donate
blood, did not confirm the CUM quoted reference intervals.

ii.

The daily means of various groups of patients over a one-month period
produced very interesting results and pose many questions for the laboratory.

iii.

4’he patient results for routine clinical chemistry analytes generated by the
CUM Biochemistry I.aboratory are deemed by international recommendations
to be of a very high standard.

2.0 Literature Review
2.1 Historical Background, Concept of Reference Values
The definition for health in the constitution of the World f lealth Organization is "a
state of complete physical, mental and social well-being and not merely the absence
of disease or infirmity". This definition has not been altered since 1948.'
After World War II there was a revolution in the hospital laboratory. It became
possible to easily and reproducibly measure dozens of analytes on a large number of
subjects. Once the analytical challenges had largely been overcome, the issue then
arose of how to interpret the data.
Concept of "Normal”: Harly descriptions attempted to define this concept. Harris and
Boyd in their book Statistical Bases of Reference Values in Laboratory Medicine, ~
credit Wootton et al as being the first to use probability distributions to describe the
results of their observations of 18 analytes in presumably healthy volunteers. ^ They
claimed that many of these distributions followed the Gaussian (bell curve)
distribution. However, these probability calculations were not used to set limits.
Values for the lower and upper limits were determined by inspection.
As more information about "normal” ranges became available, it became clear that
there were differences in what was considered “normal” among various groups of
subjects''. These observations, along with studies that indicated considerable
variations in the analytical results among laboratories, resulted in a number of
laboratories establishing their own "normal values”.
The Scandinavian Committee on Reference Values commenced their w'ork in 1969
and in 1975 they published a very comprehensive paper on ''Recommendations
concerning the collection of reference values in clinical chemistry and activity reporT
along with ''Statistical terminology’ in clinical chemistry reference values'" as a
supplement to the Scandinavian Journal of Clinical and Laboratory Investigation.^
In 1970 the Committee on Standards of the International Federation of Clinical
Chemistry (IFCC) set up The FLxpert Panel on Theory of Reference Values (FPTRV).
By 1987 this group had made 6 recommendations:
Part 1. The Concept of Reference Values J
Part 2. Selection of Individuals for the Production of Reference Values^

Part 3. Preparation of Individuals and Collection of Specimens for the Production of
Reference Values!^
Part 4. Control of Analytical Variation in the Production, Transfer and Application of
Reference Values}^
Part 5, Statistical Treatment of Collected Reference Values. Determination of
Reference Limits}'^
Part 6. Presentation of Observed Values Related to Reference Valiies^^

In 2000 rhe National Committee for Clinical Laboratory Standards (NCCLS), nowreferred to as Clinical and Laboratory Standards Institute, (CLSl) published "IPnv to
Define Reference Intervals in the Clinical Laboratory; Approved Guideline Second
Edition'. This is referred to as the NCCLS Document C28-A2, June 2000 13

2.2 Selection of Populations
I'he IFCC describes two principal types of reference individual selection, "a
posteriori" and "a priori".
".I posteriori", meaning retrospective selection, involves a large sample group,
random or non-random, which is tested for an analyte. This large group is then
subjected to exclusion criteria and partitioned.
"A priori", meaning prospective selection, where exclusion and partitioning occurs
before sampling.
I'here are advantages and disadvantages associated with each of these selections.
Figure 1 shows the NCCLS How chart for defining reference intervals, using *'a
priori" selection of individuals.
In general, these individuals will have been screened by analysing the information on
questionnaires designed for a particular analyte/s and filed out by the prospective
participants. Fxamples of the topics covered by the questionnaire would be:
•

Prior diet

•

Fasting or non-fasting

•

Abstinence from pharmacologically active substances

•

Vitamin supplement intake

•

Drug regime

(1)

REFERENCE INDIVIDUALS
comprise a

i
(2)

REFERENCE POPULATION
from which is selected a
;

(3)

REFERENCE SAMPLE
CROUP
on which are determined

i
(4)

REFERENCE VALUES
on which is observed a
;
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OBSF.RVRl)

(3)

REFERENCE

VAlXm

DISLRIBUTION

in a person may

from which are calculated

be
compared with
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( )

REFERENCE LIMFfS
that may define

(7)

REFERENCE INTERVALS

Figurel. NCCLS (CLSI) Guideline for Defining Reference Inter\af ^

•

Synchronisation in relation to biological rhythms

•

Physical activity

•

Rest period prior to collection

•

Stress

•

Smoking / non-smoking

In 1989 at the Institute of Clinical Chemistry of University Hospital, Zurich,
Switzerland, heparinised plasma of 528 blood donors was subjected to the 23 most
frequently ordered chemical and enzymatic tests'’'. The central fraction of the
distribution of all results for each test was estimated. Out of the 528 donors a
reference population was chosen. An iterative procedure for the selection was
programmed, considering the interaction between the tests, fhe derived reference
intervals are designated a "self-consistent” set of reference values.
In reality they found that only the results from 0.06 of all blood donors were within
the reference interval for all 23 variables. The result was a set of changed limits of the
fraction I' for all 23 analytes and a smaller number of observations, corresponding to a
new (smaller) reference population. The iterative procedure was repeated with all
central fractions between 0.98 and 0.90 in increments of 0.01. fhe particular fraction
used for the iterations is called F,t. Compared with their current laboratory reference
values the intervals of the "self-consistent set of reference values” were larger, the
corresponding specificity higher and the sensitivity lower.

In 1994, Kouri et al used the databases of a hospital information system in Finland, on
the basis of patient diagnosis at discharge. The nonparametric 2.5 to 97.5% "healthrelated” reference intervals were calculated for haemoglobin, mean cell volume
(MCV) and erythrocyte count for both sexes. After excluding patients with diseases
possibly affecting erythrocyte variables, they obtained a final group of 1786 women
and 1450 men, aged 20 - 65 years who were studied in age groups of 20-30, 30-45,
45-55, and 55-65 years within one year. '''
It is acknowledged that the best reference values for an individual are derived from
her or his own prior data. Because these are not often available, population-based

reference values have been widely used - usually established on healthy, non
pregnant, non-obese individuals who have neither ingested any drugs nor smoked
prior to sample collection.
The procedure for a priori selection of cpialified reference individuals from
representative populations is cumbersome; moreover, the most rigorous
recommendations for exclusion criteria may result in only a minor fraction of healthy
people being accepted. The best reference for a hospitalised patient is another patient
not affected by the disease in question, but living under the same conditions as the
patient whose laboratory result is being interpreted. The guidelines from the IFCC
accept several types of reference populations, as long as the reference groups are
sufficiently characterised.
The final discharge diagnoses collected into a hospital information system allow a
posteriori selection of relevant patients to be used as reference individuals, i.e., a
hospitalised reference population can be seen as a formally characterisable reference
category. One can argue that the clinical problem of differential diagnosis is not to
discern "health" from "disease”, but to discern a particular disease from other
diseases. In that sense, other hospital patients ma> be better references than walking
healthy individuals.
In conclusion, this study suggests that the use of computers in storing patient and
laboratory data makes it possible to combine individual discharge diagnoses,
demographic data, and other relevant information from the treatment periods within
laboratory results, thus fulfilling the IFCC recommendation for individually
characterised reference subjects. It is envisaged that when clinical doctors discover
the benefits of accurate databases created by their own efforts, they will be motivated
to iiuprove the techniques and practices in coding and storing patients’ data.

Also in 1994 H.E. Solberg discussed the fact that many scientists have investigated
the possibility of establishing reference values from hospital databases*^’. Two main
advantages have frequently been brought forward:
(a) a significant amount of money and work can be saved using data that is already
there, and
(b) the reference values obtained will match new clinical results.

Opinions differ greatly, however, as to the validity of using clinical collections of
laboratory results. Some of the arguments against it include:
(1) these methods are indirect, in a sense the reference population is identified only
through the distribution of laboratory results. The indirect method only identifies data
values that conform to some statistical criteria, usually with little being known of the
individuals from whom these values derive. The outcomes of the direct and indirect
methods may vary greatly. For example, a study in Oslo, Norway showed these
differences in serum sodium. By the direct method (central 95% reference interval in
a group of healthy adults) was found to be 135 - 148 mmol/L. Applying the indirect
(Hoffmann’s) method to 53,128 sodium values stored in the laboratory database,
yielded a very different interval: 130 - 145 mmol/L. A closer examination showed a
great fraction of sodium values in the database came from patients undergoing heart
and transplantation surgery.
(2) The “normal values” identihed by the indirect method may be heavily dependent
on the statistical criteria and statistical methods used.
Is the conclusion then that hospital data are unsuitable for the production of reliable
and useful reference values? By no means! fhe requirement is that laboratory data be
combined with information stored in clinical databases. However, often the
nformation in the clinical database is incomplete or incorrect, so that some
ndividuals that should have been excluded may pass into the group of reference
ndividuals. Such errors may be difficult to detect. Solberg suggested that one may
also imagine a useful mixed method, such as, post-treatment of the distribution of
values by one of the statistical procedures originally developed for the indirect
method.

Deriving reference values for older patients is particularly problematic, because agerelated physiological changes are known to occur, and the prevalence of sub-clinical
disease increases markedly with advancing age. In 1998 healthy reference
haematological values were estimated from a cross-sectional survey of a population (n
= 4433), ages 49 years or more, residing permanently in a defined geographical region
west of Sydney. These subjects were participants in the Blue Mountain Lye Study.
For each haematological index, potential confounding factors of interest were
smoking status, high alcohol intake, medication, self-reported chronic disease, and

high creatinine values. Where there were significant differences (/^<0.()5) between
mean values by unpaired ^test, the subject was excluded for that haematological
index. Fhe distribution of each haematological characteristic in the reference subjects
was tested for departure from the Gaussian distribution by using the Shapiro-Wilk
statistic. In this study, the authors argue that it is entirely appropriate to compare
haematological test results from older adults with those of this study. Data from
healthy young adults may not be ideal for the evaluation of test results from an older
patient.

Also in 1998 Horn et al proposed a new methodology for the estimation of reference
intervals for data sets with small numbers of observations or for those with substantial
numbers of outliers \ In this case, in Cincinnati, US, they found it virtually
impossible to obtain sufficient numbers to determine the reference interval for the
metabolism of the drug lidocaine into its metabolite methyxylidide because it was
difficult to get volunteers who were both healthy and willing to be injected with
lidocaine. four reference interval procedures (nonparametric, transformed, robust
with a nonparametric lower limit, and a transformed robust) were compared for
sample sizes of 20, 40, 60, 80, 100, and 120 from

distributions of 1,4, 7 and 10 df.

distributions were chosen because they simulate the skewness of distributions often
found in clinical chemistry populations, fhe root mean square error was used as the
measure of performance and they used computer simulation to calculate this measure.
I'he robust estimator showed the best performance for all sample sizes. .As the sample
size increased, the performance values converged, fhe reference intervals were
calculated with and without outlier detection. It was proposed that robust statistical
analysis could be of great use for determinations of reference intervals from limited or
unreliable data.
fhe second approach was based on transforming the data to achieve normality,
computing the appropriate quantile estimators using normal theory, and back
transforming the data to the original scale, fhe transformation used was that
described by Ilanis and Boyd.
fhe z-data were then tested for normality by using the Anderson-Darling statistic at
significance level 0.15. If the null hypothesis of normality was not rejected, then the

traditional normal quantile estimates were used on the z-data. On the other hand, if
normality was rejected, then the nonparametric (Harrel and Davis) reference interval
was used.
However, because none of the procedures did particularly well when confronted with
severe contamination, the importance of ensuring the quality of the data and the data
collection process cannot be overstated when determining reference intervals. This
study recommends that nonparametric, robust, and nomial theory (on transfomied
data) reference intervals be computed in practice. If they are in agreement, then any
one will do reasonably well for reporting pui*poses. If the methods disagree, they
believe that the tightest interval should be used - preferring to err on the side of more
false positives, than false negatives, thus forcing the clinician to further evaluate the
patient.

In 2005 in Milan, Grossi et al found that it is particularly important to compare
patients’ results with reference intervals derived from a matched population by use of
defined statistical methods''^ Laboratory results over a 3-year period (-15 000 000
records; 197 350 individuals) were retrieved from their laboratory information system.
An inclusion/exclusion procedure for individual patients was applied based on {a)
presence of at least 1 of 23 previously defined "basic tests"; {h) only 1 measurement
per test by the laboratory over the 3-year period; (c) for each test, absence of any
abnormality in the correlated tests. Before the third step, correlations among quantities
were assessed by a Spearman correlation matrix, comparing each of the 23 basic tests
with all remaining tests by use of a novel multivariate algorithm. The initial sample
group (n = 197 350) was reduced stepwise by the selection criteria to 166 027, then to
93 649, and finally to 61 246 individuals constituting their reference sample group.
Results from the last 2 groups were used to calculate sex-specific, and in some cases
age-related, reference limits for the 23 basic tests and for 13 additional quantities.
Reference limits were calculated throughout this study by nonparametric estimation of
percentiles. The study concluded that reference values derived by retrospective
analysis of large samples of data obtained at a given institution are particularly
suitable for the evaluation of results for the presenting patient population at that
institution.

2.3 Determination of Reference Intervals
2.3.1 Introduction
According to the Ih’CC recommendations, in the usual clinical situation, the reference
interval merely serves as a basis for a more or less intuitive assessment of biological
information given by an observed value”. Reference intervals defined by fractiles are
the most commonly used type. It is a frequently used convention that the reference
interval should contain the central 0.95 fraction (or 95%) of the reference distribution.
The fractiles should preferably be accompanied by confidence limits around each
limit (e.g. 0.90). Fractiles may be estimated by non-parametric or parametric methods.
Non-parametric (or “distribution-free”) techniques make no assumptions about the
type of distribution. Parametric estimation techniques require that the data fit a
specified distribution type (usually Gaussian), or that such a distribution is
appro,ximated by the application of transforming functions to the data (e.g. using
logarithms of the measured data).

Parametric estimates are theoretically more

precise provided the assumption of distribution type is valid. F3ut the type is usually
not known in a priori. I'he non-parametric method is recommended for general use
because of its simplicity. Determination of the 0.025 and 0.975 fractiles requires at
least 40 values. I’o obtain reliable estimates the number of values should be at least
120.

2.3.2 Non-Parametric Method.
fhe If'CC Recommendations state that there are several non-parametric methods for
estimating a tractile (percentile); the rank-based method is described here”. Sort the
.V reference values according to increasing numerical values and assign rank numbers
such that the lowest value has rank number 1 and the highest value has rank no.
< \2... < X ,v.

N: x\

lies (values that are equal) may be avoided by using more decimal

places than are usually used for reporting patient results. Compute the rank number of
the 0.025 fractile as 0.025 (A+l) and that of the 0.975 tractile as 0.975 (yV+l). Set the
lower reference limit equal to the reference value corresponding to the rank number of
the 0.025 fractile and the upp(5r limit that of the 0.975 fractile. Then determine the
two-sided 0.90 confidence interval of the population 0.025 fractile and the 0.975
fractile. (Unlike the IFCC recommendations, the parametric method is not even
described in the NCCLS guideline’^)
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2.3.3 Parametric Method:
Step 1 involves testing for Gaussian distribution using statistical tests ofgoodnessof-fit. The parametric method assumes that the distribution of reference values is
close to the Gaussian distribution." If the data seem to fit a Gaussian distribution
then one can estimate fractiles directly. The hypothesis is that the differences between
the reference distribution and the Gaussian distribution are only due to chance. This
hypothesis is rejected when the observed differences make it very improbable. In that
case the sample distribution is declared non-Gaussian. The graphical procedure of
plotting the cumulative values on Gaussian probability paper may give a picture of
any gross deviations from Gaussian shape. Evaluation of the deviation may be
difficult because the ordinate (probability scale) is non-linear. The KolmogorovSmirnov’s test evaluates these deviations. Here the test statistic Dmax is equal to the
greatest vertical difference observed in the probability plot, taking into account the
nonlinearity of the probability scale. I'he greatest difference fTuax between the
distribution of the reference values and the hypothetical Gaussian distribution is
calculated as follows;
f)"^ = ma.x (i/N
D'

w,)

ma.x (vf, - (i - /)/V)

where ( i = 1..........V)

= max (DT D')
fhe hypothesis that the data fit a Gaussian distribution is rejected at the 0.05
significance level if the value of Dmax is > 0.886 / vW where ;V is the sample size (A' >
30). The critical value of Dmax is 1.03 1/Va'

at the 0.01 significance level,

fhe Anderson-Darlingfs test is even more powerful (i.e. more likely to reject the
hypothesis of Gaussian form when the hypothesis is false).

Many studies of the

performance of goodness-of-fit tests are based on distributions never seen in
biological data. However, the estimation of its test statistic A“ needs somewhat more
calculation than is necessary for Dmax procedure, and is outlined as follows:
Sort the reference values according to numerical values: .\i < X2... < x \ then,
for /
V =

1,............, A’, compute the deviations
(X| - X

)/

Sx,

using the mean x and SD

Sx

of the reference values.

From the deviations v, find the values w, of the cumulative Gaussian distribution
function in statistical tables e.g. in scientific tables"' or by using an appropriate
■)

algorithm on a computer e.g. the REFVAL programme.““

The test statistic A"" is calculated as follows:
a'

- - N - [mi - 1) ({ln(vv,) + In (1 - w .v,/.,)}] / N),

The hypothesis that data fit a Gaussian distribution is rejected at the 0.05 significance
level if the values of the size-adjusted test statistic
(1 + 4//V - 25 / N^) is > 0.787
The critical value at the 0.01 level is 1.092.
Correction for rounding of data: two methods are suggested: (i) Random noise may
be added to each reference value .v, before performing the tests."'’ (ii) The
Kolmogorov-Smirnov's test may be performed on the 2N values by adding and
subtracting S / 2 to each reference value x,.
Calculate the Coefficients of skew ness gs and kurtosis gk: these are statistical
measures of the distribution’s asymmetry and peakedness, respectively. Their values
show the type of deviation from the Gaussian distribution (where gs = 0, and gk = 0)
gs
gs

< 0: negative skewness (too long left tail)
> b: positive skewness (too long right tail)

gk < 0: negative kurtosis (too tlat-topped and short-tailed as compared to
Gaussian)
Sk > 0: positive kurtosis (too peaked and long-tailed as compared with Gaussian)
Reject the hypothesis that the sample values have a Gaussian distribution if the
absolute value of one or both coefficients is > 2.6 times their corresponding SD.

Step 2 involves the transformation of data - Distributions of biological quantities
are often asymmetric, positive skewness being the most frequent abnormality.
Experience has shown that the frequently observed positive skewness often is
corrected sufficiently by the simple logarithmic or square root transformations of
data, fhese functions are especially useful when data are treated manually or by a
calculator. More general transformations need the assistance of a computer since a
function parameter has to be estimated, e.g., by an iterative process (a converging
trial-and-error repetitive routine) guided by the coefficient of skewness. Examples of
mathematical functions suitable for transformation of data to symmetry are the
modified logarithmic function yv = ln(.v / + c), the power function of Box and Cox 24
and the exponential function suggested by Manly.When applied to positively
skewed data with values greater than zero, these three functions produce
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approximately equal results. Several funetions for the correction of non-Gaussian
kurtosis have been suggested: the hyperbolic sine function corrects for negative
kuitosis, the inverse hyperbolic sine function corrects for positive kurtosis. The
power function of Boyd and Lacher"^, and the modulus function of John and Draper
may correct for both positive and negative kurtosis"^. All these functions assume that
the original distribution is symmetrical or that the data has been transfonned to near
symmetry by choosing a transform which makes the coefficient of skewness zero.
Input data should be standardised to zero mean and unit variance by subtracting from
each value the mean and dividing by the standard deviation. These transformations
need the assistance of a computer since the function parameter has to be estimated,
e.g., by an iterative process guided by the coefficient of kurtosis.
Step 3: Estimation of fractiles and their confidence intervals: For a Gaussian
distribution, a central 0.95-interval obtained by calculating the limits arithmetic mean
- 1.96.SD and arithmietic mean + 1.96 SD, is recommended.”
Figure 2 illustrates distributions that are normal (Gaussian), skewed and kurtotic.

2.3.4 Intuitive Method
There are no general rules that can be given for the intuitive assessment of a
population, as it has to suit the particular case.” The IT'CC recommendations
acknowledge that sometimes there are situations where professional judgement is
used to investigate particular populations. However, all aspects of the selection
process must be documented. Computer simulations of populations may also be
studied, again once the criteria for inclusion and exclusion are well documented.
In 2000 both the simple nonparametric reference interval estimation procedure and
the resampling (boot-strap) principle were studied by Linnet using simulations based
on distribution types that should be relevant for clinical chemistry i.e., Gaussian and
skewed distributions.^'^ The bootstrap principle consists of repeated random
resampling of the original observations with replacement. Each of the original
observations is assigned the same probability of being resampled. For each set of n
resampled values, percentile estimates are computed as usual. After repetition of the
procedure a large number of times e.g. 50-500 times, the bootstrap estimates are
obtained as the means of these percentile estimates. In this study 100 replications
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were carried out. The root mean square error (RMSE) of percentile estimates
represents an overall measure of bias and imprecision for a given procedure and
allows a ranking of the studied procedures. They found that the differences between
the procedures were most pronounced at low to moderate sample sizes. A valid
statistical estimation method should provide a realistic estimate of the uncertainty
associated with the procedure, e.g., expressed as a 90% confidence interval. The
general, approximate relationship between standard error (SE) and sample size is that
of a square root relationship:
to halve the SE, a fourfold increase in sample size is needed.
The SE of the percentile estimate is presented here as a percentage of the width of the
reference interval to make the relationship generally applicable. The approximate
90% confidence interval is obtained as ± 1.65 SE around the percentile estimate. For
a sample size of 120, the 90% confidence interval corresponds to approximately ±
10% around the percentile in case of a Gaussian distribution, and approximately ±
25% for the skewed distribution {the percentage of the width of the reference interval.
It is advisable to apply the bootstrap procedure mainly at sample sizes exceeding 100.
fhis procedure is related to the weighted percentile method suggested by Harrel and
Davis. Percentiles are estimated as a weighted average of all possible percentiles,
which may reduce the RMSE by ^ 10-15% for a sample size of 119.

2.3.5 Parametric versus Non-Parametric iVIethocIs
Parametric
In a study in Wales in 2004, PCoduah et al introduced a new criterion, the percentile
inclusion probability, for comparing methods for calculating reference intervals^^\ The
criterion was compared with a previously published measure of reliability (suggested
by Ldnnet in 1987), the ratio of the width of the confidence interval for the percentile
to that of the reference interval.'^' Data were simulated from a range of theoretical
statistical distributions representing the shapes of data sets encountered in clinical
investigations. The two-stage transformation of the data to a gaussian distribution
recommended by the IFCC was compared with a nonparametric approach, fhe

14

percentile inclusion probability criterion identified that the parametric approach is in
some cases seriously affected by bias.
Using different parametric models, they compared nonparametric and parametric
methods for two sets of clinical data (distributions of birthweights for full-term male
births in Wales 1988 - 1997 and neonatal TSH values on newborns in Cardiff in
2003) and showed that the parametric approach is susceptible to model choice.
They concluded that sample sizes significantly greater than those cun'ently
recommended are required to establish reference intervals, regardless of whether
parametric or nonparametric methods are used. Parametric methods are preferable
when the data are truly Oaussian, but are only marginally better than nonparametric
methods when data transformation is needed to achieve a Gaussian shape.

Non-Parametric
Another study by Griffiths ct al described methods of calculating reference intervals
where these centiles vary with a covariate, usually age or time. They proposed a non
parametric procedure that relies on the principles of regression and show how sample
size determination can be assessed. “ They used three different datasets:
(i) results of cholesterol on 883 females in Wales (fleart Beat Wales),
(ii) data on newborns in Ncwcastle-on-Tyne in 1986, and
(iii) maternal serum a-fetoprotcin concentrations.
They also showed how the sample size calculation is intluenccd by the distribution of
the times measured. They illustrated their method on the three data sets and compared
the results for their proposed nonparametric method with parametric estimates. They
showed that, with their method, the bias is reduced and that the nonparametric method
is less likely to produce tluctuating profdes. They concluded that to achieve adequate
precision the sample size needs to be larger than 120, as has often been recommended.
If there is doubt about the parametric model, then threshold sample sizes may need to
be as high as 500.

In 1999 Horn et al proposed the use of a robust estimator because it is more tolerant
of outliers, fhey then applied and compared this with both the traditional
nonparametric and parametric analysis in determining reference intervals for a wellstudied population, the Fernald Medical Monitoring Program (T) and a computer
generated sample (W). ’ ' They evaluated samples from the two populations and
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reference intervals were calculated for 27 analytes, two genders, and six age groups
for males and seven age groups for females. The T population of 2948 were entered.
Only participants who were scored a 5 or a 6 (“healthy”) were used for the initial
calculation of reference intervals. The W group w'ere drawn from the general
population pool. This was the Wide Age Range Population group. Where a
transformation of the data for a particular test to a Gaussian distribution was not
possible or if the Anderson-Darling test rejected normality, the reference interval was
not computed.
Their recommendation for the development of reference intervals included both
nonparametric and robust estimators. Both of these techniques should yield similar
results. If they do not agree, then consideration must be given to the possibility that a
significant part of the sample could have diseased individuals or that multiple
populations are being measured.

2.4 Observing the Distribution
According to the IFCC recommendations the distribution of reference interval results
should be visually inspected graphically, in a histogram. One should look for
skewness (asymmetry), kurtosis (peakedness), outliers and bi- or poly-modality. A
hi ' poly-modal distribution has two ' more peaks". Figure 2 illustrates some typical
histograms of distributions of biological data. Figure 3 in section 5 shows an example
of outliers in a distribution.
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Compared with the Normal
distribution, the platykurtotic
distribution is flatter with fewer
values near the mean and the
leptokurtotic distribution is more
peaked with more values near
the mean. In laboratory medi
cine a right skewed distribution
in a control group often
becomes Normal after logarith
mic transformation; a left
skewed distribution may be
caused by contamination with
values of clinical significance
and is characteristic of serum
albumin and total protein values
from a hospital population.

Figure 2. Normal, Kurtotic and Right and Left Skewed Distributions 28

2.5 Partitioning
Collected values may be partitioned into subclasses to reduce variation. Statistical
tests of differences in location (Student’s t test, analysis of variance, etc) of
differences in intra-class variation (Fisher’s Ftest Bartlett’s test, etc) between
possible subclasses may indicate the need for partitioning of the set of values.^"^ If the
set of reference values has been partitioned, each subclass must have sufficient
numbers (i.e.l20).

Reference intervals for calcium, phosphate, and alkaline phosphatase were derived,
based on age and sex by Sinton et al, using profile results of over 20,000 subjects in
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Australia in 1986.'^^ They advocated the simplest technique tor testing whether
stratification of reference intervals was necessary. In the absence of a skew, they
proposed that a pre-analytical variable should shift the mean by >25% of the reference
interval before a separate interval becomes justifiable. This is an arbitrary criterion
but a reasonable one.
Harris and Boyd’s work on data from medical students in Virginia in 1990 deals with
two subgroups only because the statistical ideas can be expressed much more simply
for two groups; moreover, comparison of three or more groups can always be reduced
to differences between groups in pairs.
The variance

(f

of a combined population of subgroups is given by
= Mean

where

(f, -

is the variance and

Variance //„

(1)

the mean of the /'th subgroup. In the case of two

subgroups of equal size, equation 1 may be written,
=(rf,-/2)(l

^

(Hi -|,i2)-/4

(2)

where R = 62 / bi > 1
For R > 1, the standard deviation 6 of the entire database will always be greater than
61, the smaller of the two subgroup standard deviations. On the other hand, 6 will be

less than 62, the larger subgroup standard deviation, when the variance of the means is
less than 62' (R“ - I )/2R“.
Substituting R = 1 and denoting by 60 the common within-group standard deviation,
equation 2 reduces to
(f

= 60'' > (pi -

(3)

Using examples from a database of many analytes measured in blood samples
collected from three successive classes of medical students during 1987 and 1988 at
the University of Virginia Health Sciences Center, random samples of 800 normal
deviates drawn from each of two paired (laussian distributions were used. The first
was the standard Gaussian distribution with mean pi == 0 and the standard deviation 6\
=

1. The second was a Gaussian distribution with mean p2 > d and standard deviation

62 > 1. fhe ratios of the standard deviations, R = 62/bi (where in this case 61 = 1),

were set at 1.0, 1.3, 1.5 and 2.0. The mean to was assigned a value according to the
general formula
N(q, -p2)'/di'(l -R“) = r,

(4)

where this ease

)lIi

= 0, and 6i = 1, so that \ii = z[{ \ + R 2 )/N] I /2 . The statistic z was

assigned one of the values 0, 1,2, 4, 6, or 8. The value of )li2 foi' a given values of z
and R was calculated for N = 120. The same (a? for another value of N would
correspond to a different z-value. fhis distinction becomes important when specific
recommendations on threshold z-values for deciding whether or not to calculate
separate reference ranges, fhey conclude, therefore, that the criteria for partitioning
into subgroups (at least by age and sex) should not be too stringent, especially if
supported by physiological understanding.
It follows from this reasoning that one would derive a numerical decision point on the
question of whether or not to partition reference ranges from graphs rather than
equations and tables. Attention should be paid to the ratio of standard deviations (R)
as vvell as the difference between mean values before deciding on the need for
separate reference ranges. Specifically, when R is <1.5. the value z* = 3 appears to
represent a difference between subgroups Just large enough to justify separate ranges.
However, this threshold (or ''criticaf*) value, z (e.g., = 3). corresponds to a sample
size of N = 120 from each subgroup. For another size N. z would be given by
3(N/120)"^
fheir recommendations include:
i.

fhe possibility of subgroup ranges should be considered before population
sampling is undertaken, and pertinent physiological information as well as
clinical practice should be evaluated.

ii.

If specified subgroups are supported by such information, initial sample sizes
of, say, 60 measurements in each subgroup should be collected.

Hi.

If the ratio of subgroup standard deviations exceeds 1.5, sampling should be
continued to obtain at least 120 in each subgroup, and separate reference
ranges should be calculated, regardless of whether the means are significantly
different statistically.

iv.

If the ratio of standard deviations is less than 1.5 (which will usually be the
case), but the usual normal deviate statistic based on 60 observations for
testing the dift^rence between two subgroup means exceeds 2.12, continue
sampling to obtain 120 measurements in each subgroup and repeat the
statistical tests. If the ratio of standard deviations remains below 1.5, and the
normal deviate test does not exceed 3, the samples should be combined and a

single

reference

range

calculated.

Otherwise,

separate

ranges

are

recommended, assuming, as stated, that physiological knowledge and clinical
useful-ness support such partitioning.

In 2002 Lahti et al suggested critical values as partitioning criteria for percentages of
subgroups outside each reference range, derived from analytical bias quality
specifications for using common reference intervals throughout a geographic area^^.
As alternative partitioning criteria to the actual percentages, these were transformed
mathematically to critical distances between the reference limits of the subgroup
distributions, to be applied to each pair of reference limits, the upper and the lower, at
a time. The new criteria were tested using data on various plasma proteins collected
from 500 reference individuals, and the outcomes were compared with those given by
the currently widely applied and recommended partitioning model of Harris and
Boyd, the "I larris-Boyd model". They suggested 4.1% as the critical minimum
percentage outside that would justify partitioning into subgroups and 3.2% as the
critical maximum percentage outside that would justify combining them. They found
that the distance criteria, applied separately to both reference limit pairs of the
subgroup distributions, seemed more reliable and correlated more accurately with the
critical percentages than the distance criteria of the I larris-[3oyd model. As opposed to
the Harris-Boyd model, the new model was easily adjustable to new critical values of
the percentages, should they need to be changed in the future.

Later the same year, the same group (Lahti et al) described a model based on
controlling the proportions of the subgroup distributions that fall outside each of the
common reference limits, using the distances between the reference limits of the
subgroup distributions as functions to these proportions.They examine the
significance of the unequal prevalence effect for the partitioning problem and quantify
it for distance partitioning criteria by deriving analytical expressions to express these
criteria as a function of the ratio of prevalences. Dramatic shrinkage of the critical
distances between reference limits of the subgroups needed for partitioning was
observed as the ratio of prevalences, the larger one divided by the smaller one, was
increased from unity. Because of this shrinkage, the same critical distances are not
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valid for all ratios of prevalences, but specific critical distances should be used for
each particular value of this ratio.
Although proportion criteria used in determining the need for reference interval
partitioning are not dependent on the prevalence effect, this effect should be
accounted for when these criteria are being applied by adjusting the sample sizes of
the subgroups to make them correspond to the ratio of prevalences.
The study detailed methods to account for the prevalences when applying each of
these types of criteria. Analytical expressions for the distance criteria, to be used
when high precision is needed and approximate distances to be used in practical work,
are derived. General guidelines for partitioning Gaussian distributed data were
presented. Following these guidelines and using the new model, they suggested that
partitioning could be performed more reliably than with any of the earlier models
because the new model not only offers an improved correspondence between the
critical distances and the critical proportions, but also accounts for the prevalence
effect.

Lahti, Petersen. Boyd, F<ustad and Solberg recently proposed partitioning criteria for
Gaussian distributions relate to proportions of the subgroups outside each of the
reference limits of the combined distribution (proportion criteria) and to distances
between the subgroup distributions as correlates of these proportions (distance
criteria).However, distance criteria do not seem to be ideal for non-Gaussian
distributions because a generally valid relationship between proportions and distances
cannot be established for these. They found that proportion criteria appear preferable
to distance criteria for two additional reasons:
{a) the prevalences of the subgroup populations may have a considerable effect on

stratification, but these are hard to account for by using distance criteria. Two methods
to handle prevalences are described, the root method and the multiplication method.
{h) tied reference values, another complication of the partitioning problem, could also

be hard to take care of using distance criteria. Some solutions to the problems caused
by tied reference values are suggested. Partitioning of biochemical reference data
should preferably be based on proportion criteria; this is particularly true for nonGaussian distributions. Both of the described complications of the partitioning
problem, the prevalences of the subgroups and tied reference values, are hard to deal
CORK INSTITUTE Oh rECHNOLOtA*

with using distance criteria, but the proposed methods in their study make it possible
to account for them, when proportion criteria are applied.

2.6 Dealing with Outliers
The IFCC recommendations on aberrant values and outliers state that values
identified as possible outliers should not be discarded automatically. They must be
investigated and best judgement used about their inclusion/'exclusion. Decisions
should be recorded. Aberrant values should be corrected or discarded.'' The NCCLS
(CLSl) guideline recognises that outliers in the data are a real possibility.''^ However,
the recommendation is that unless it is known that such points are aberrant for known
reasons (e.g., a mistake in the analysis), attempts should be made to retain the values
instead of deleting them. To test for outliers the NCCLS recommend the Dixon test,
which is as follows:
Let R = the range of values (maximum-minimum) and let D = the absolute difference
between the most extreme (large or small) value and the next most value (large or
small). If the ratio D R exceeds 1/3, then the extreme value in question is deleted. If
there are two or three outliers on the same side of the sample this rule may fail.
Therefore it is recommended that the least extreme outlier as if it were the only
outlier. If the D/R test rejects this then the more extreme outliers are rejected as well.

In 2001 Horn et al proposed that the removal of outliers before analysis, may yield
better estimates of the reference interval for both robust (explained below) and
nonparametric estimators.They used the National Health and Nutrition
Lxamination Survey (NHANES III) data and Fernald Medical Monitoring Program
(population of residents who lived near a nuclear feed plant near Cincinnati) data
because the health status of these populations is well documented medically. Treating
the known healthy individuals as a "gold standard”, they examined the effect of the
addition of nonhealthy individuals on these estimators. Outlier detection methods are
mathematically valid based on assumptions about the underlying distribution, which
often is assumed to be Gaussian. If such a technique were used on skewed data, it is
not clear that the outlier detection would achieve its goal. It could be that many good
values could be deemed outliers and thus omitted from calculations, possibly making
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the resulting reference interval unreasonably narrow. On the other hand, if there are a
large number of outliers that "mask” their aberrant location, the outlier detection
scheme will not llag enough values to be omitted. This could make the resulting
reference interval unreasonably wide. Thus, there is a trade-off between these two
situations. A two-stage outlier detection scheme was proposed that would attempt to
balance the two situations. This method would first transform the entire sample to
achieve an approximately Gaussian random sample using the Box-Cox transformation
method. Then, the robust approach to labelling outliers from a Gaussian distribution
as described by Tukey was used.
This stage involved the labelling of extreme values using only the middle 50% of the
sample. It involved the computation of the lower and upper quartiles (i.e., the 25 and
75 percentiles) of the transfomied data. Call these statistics, 0\ and 0^. The
interquartile range (IQR) or

- 0\ was then computed. Lastly, the lower fences and

upper fences were computed as follows: lower fence = Gi - 1.5(IQR); upper fence =
G3 +- 1.5{IQR). Any transformed data over the fences were considered as outliers and
the original data points are omitted from subsequent reference interval (RI)
estimation.
Using the NHANLS III and the Fernald data sets to examine the performance of the
outlier removal they ran a simulation consisting of 1000 replicates of sample size
n=120. Fhey considered 33 different analytes, fhe Reference Interval Width (RIW)
was examined because it is insensitive to additive bias and ratios of these widths
allow comparison across analytes. RIW is defined as the difference between the (1a/2) X 100% and the (a/2) x 100% of the group under consideration. In this report
they examined 95% RIW, i.e., a = 0.05.
The nonparametric estimation procedure is the traditional one based on the observed
upper and lower endpoints, or percentiles. The RIW is the difference between these
two values. The robust estimator of the upper endpoint of the reference interval w^as
based on a function that smoothly down-weights observations based on their distance
from the median. Only observations greater than or equal to the median were used,
and the weighting function was the biweight described by Horn. The robust estimator
of the lower endpoint was a smoothed version of the nonparametric estimator
described by Harrell and Davis

and used by Horn. ' The RIW was calculated using

the traditional nonparametric 95% reference intervals and the robust estimator, with
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both methods using the proposed outlier detection. I'hey choose the ratio of RIWs as
the measure of the effect of inclusion of nonhealthy individuals (RIW based on the
total group divided by RIW based on the healthiest in the group). I'o average across
variables, the logarithm of this ratio was used because the means of these values are
not biased.
To compare the accuracy of the RIW estimators with and without outlier detection,
the root mean square error (RMSE) was examined. For each sample, the RIW was
computed, the ideal RIW was subtracted from it, and the difference was squared.
(The ideal RIW for each distribution is the difference between its 97.5 and 2.5%
percentiles) fhese squared differences were averaged over the 1000 replications, and
the square root was taken, yielding the RMSE. When the outlier detection scheme was
applied to the NUANPiS and Fernald data sets outliers w^ere found in every case.
This study reported that the robust approach was more affected by outliers than the
nonparametric approach. The inclusion of nonhealthy individuals increased the width
of the reference interval. The nonparametric RIW was more affected by the presence
of the nonhealthy than was the robust RIW. The problem is that health status is
difficult to validate. The problem of including unhealthy individuals in the estimate
of reference intervals is a real one. I'his study demonstrated that, for almost every
one of the 33 analytes, the RIW was wider for the total group than for the healthiest
group.

In 2005 Solberg and Lahti studied the specificity of Horn’s test algorithm (probability
of false detection of outliers), using Monte Carlo computer simulations performed on
13 types of probability distributions covering a wide range of positive and negative
skewness^” Distributions with 3% of the original observations replaced by random
outliers were used to examine the sensitivity of the test (probability of detection of
true outliers). 3'hree data transformations were used;
i.

the Box and Cox function (used in the original Horn’s test).

ii.

the Manly exponential function, and
the .lohn and Draper modulus function.

For many of the probability distributions, the specificity of Horn’s algorithm was
rather poor compared with the theoretical expectation. The cause for such poor
performance was at least partially related to remaining nongaussian kurtosis
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(peakedness). The sensitivity showed great variation, dependent on both the type of
underlying distribution and the location of the outliers (upper and/or lower tail). It was
concluded that, although Horn’s algorithm undoubtedly is an improvement compared
with older methods for outlier detection, reliable statistical identification of outliers in
reference data remains a challenge.

2.7 Quality Specifications for Analyte Performance in Reference
Intervals
d'he International Organisation for Standardisation (ISO) defines quality as
"the totality of characteristics of an entity that hear on its ability to satisfy stated or
implied needs'" The essential elements of quality laboratory practice, quality
assurance, quality improvement and quality planning must be included in quality
management. All definitions of quality can be interpreted in our field as: establishing
conditions such that the cfiiality of all tests performed in laboratory medicine assists
clinicians in practicing y^ood medicine. Therefore, we must know exactly what level
of quality is needed to ensure that satisfactory clinical decision-making is possible.
The currently most widely used term for this level of performance required is ’’quality
specifications” Other terms include ‘’quality goals”, ’’quality standards”, ’’desirable
standards”, ’’analytical goals”, and ’’analytical performance goals”. Ideally, quality
specifications should be available for each and every performanee characteristic of
laboratory procedures, particularly for reliability characteristics, and especially for
precision and bias. To implement a proper laboratory quality management system, we
must be able to define quality specifications for precision and bias, and then for total
error allowable.
2.7. J Influence of Performance on Reference Values
Clearly the dispersion of the reference interval will depend on the analytical precision.
However bias is more important. Reference limits are set to ensure that 95% of
population values are lie within the reference interval. Thus, 2.5% of the group will
have values above, and 2.5% below the reference limit. If a method has a positive
bias, more than 2.5% of the group will have values that are above the upper reference
limit and less than 2.5% will have values below the lower limit. Because of the bell-
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shape of the Gaussian distribution, the increase above 2.5% at the upper limit will be
greater than the decrease below 2.5% at the lower reference limit,

fhe effect is that

there will be more clinical false positives than false negatives. The end result is that
more than (the desired) 5% of people will be classified as unusual - having values
outside the reference limits. Similarly, if the method has a negative bias, then more
than 2.5% of the group will have values lower than the lower limit and again, because
of the bell-shaped distribution, the 2.5% decrease below the lower reference limits
will be greater than the 2.5% increase above the upper reference limit. The result is
again that more than (the desired) 5% of people will be classifed as unusual - having
values outside the reference limits.
2.7.2 The Total Krror Concept
fotal error (TFG can be calculated in a number of ways. The most usual way is to add
bias and precision ’linearly". In these calculations it is the absolute value of the bias
that is used. It does not matter if the bias is positive or negative.
Much of the basic literature on the theory and practice of quality planning uses the
following formula for total error allowable (Tfa):
fotal r.rror Allowable = the sum of the bias plus 1.65 times the precision, or
I F,a =bias t- 1.65SD(orCV)^^
This formula is derived as follows:
Working at 95% probability to allow for 5% error, the values to be excluded are only
at one side of the distribution, fhus 5% is excluded at both the upper and lower ends
of the distribution; 10% in total, 'fherefore only 90% of the distribution is included
and the appropriate multiplier is 1.65. These multipliers are known as Z-scores.
The formula for total error allowable then becomes
total error allowable - bias + Z (precision), or
total error allowable = bias + 1.65 (precision) for 95% probability, or
TTa =^1|a+ 1.65CVa
Note: SD is used when working in terms of the units for reporting results,
CV is used when variations and errors are considered in terms of percentages
CV% = SD/Meanx 100%
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2.7.3 The Hierarchy of Strategies to Set Quality Specifications
A conference was convened in Stockholm in April 1999 to discuss global strategies to
set quality specifications in laboratory medicine. There were participants from 23
countries in attendance. The papers and consensus statement have been published in a
special issue of the Scandinavian Journal of Clinical and Laboratory Investigation.
The consensus statement set the available models into a hierarchical structure, based
on proposals in an earlier editorial in Clinical Chemistry. Models higher in the
hierarchy are preferred to those lower down.^^ Table 1 shows the summary of the
consensus agreed at that meeting.

Table 1. Consensus Summary of the Hierarchy of Strategies to Set Quality
Specifications
Rank/ Strategy

Subclasses

Level
.

1

Assessment of the effect of

Quality specifications in specific

analytical performance on specific

clinical situations

;

clinical decision making
2

As.sessment of the effect of

A. (jcneral quality specifications based

analytical performance on general

on biological variation

clinical decision making

B. Oeneral quality specifications based

j

on medical opinions
Professional recommendations

A. Ciuidclines from national or
international groups
B. Guidelines from expert individuals
or institutional groups

4
1

Quality specifications laid down

A. Quality specifications laid down by

by regulation or by TQAS

regulation

organisers

B. Quality specifications laid down by
TQAS organisers

i

5

Published data on the state of the

A. Published data from PT and EQAS

art

B. Published individual methodology
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A brief description of each level of the hierarchy of quality specifications is now
given; however, these models are not set in stone because new and better models may
become available.
Level 1: Quality specifications in specific clinical situations
Ideally, quality specifications should be derived by numerically accessing the effect of
analytical performance on specific clinical decisions, fhus, test-by-test, and clinical
situation by clinical situation, we derive quality specifications directly related to
clinical outcomes. This approach is very difficult and the calculations have been done
for very few analytes in a limited number of different clinical settings,
fake serum cholesterol screening test as a theoretical example of this. One assumes
that serum cholesterol has distribution that is Gaussian and that there is wide
agreement on a fixed concentration for action. If the laboratory’s analytical bias is
positive, then the curve will move to the right and a greater number of the population
would now be above the chosen fixed limit for clinical decision-making, both those
with genuinely high levels and those whose level was high simply because of the
positive analytical bias. Thus "false positives” would be found, fhis could lead to
unnecessary recalling, retesting, diet advising, drug administering and follow-up
clinic visits. See Fig. 3.
In contrast, if the laboratory's bias were negative and the curve moved to the left,
some people with a serum cholesterol concentration above the fixed limit for clinical
action would have low values because of the bias. Thus the number of "false
negatives” would increase. This would lead to cost savings on additional testing and
drugs in the short term but potentially huge costs in the long term, as some of the
population missed at the initial testing would potentially succumbe to premature
coronary heart disease. See Fig.3.
fhe effect of positive and negative biases on the fraction of the population at high risk
can be easily derived from knowledge about the simple mathematics of Gaussian
distribution: by calculating the percentage of people inside and outside the fixed limit,
and doing this for a number of bias values. Then the relationship between analytical
bias and the decreases and increases in the percentage of the population at risk can be
calculated and plotted.
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No Bias

Positive Bias

True Positives

Figure 3. Effect of Bias on Outcomes using Serum Cholesterol Assays44

If we could define medical needs in terms of percentage misclassification allowable,
the analytical bias allowable-the quality specification-can be easily interpolated. If
clinicians agreed that it was satisfactory for 5% of people to be incorrectly classified,
then we could allow an analytical bias of ± 3-4%.
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Bias is the most important performance characteristic when using fixed limits for test
interpretation. However, a major disadvantage is that most tests results are used in a
variety of clinical settings, and only a few tests are used in single well defined
situations with standard well-accepted medical strategies directly related to the test
result. Another drawback is that the calculated quality specifications depend on
assumptions about how clinicians actually use numerical test results. This has been
difficult to document 44

Level 2: Quality specifications based on general clinical uses of test results
Clinical laboratory test results are used for many purposes. The two major clinical
settings for using test results are:
1. monitoring individual patients
2. diagnosis or case find using reference intervals
Both of these show that generally applicable quality specifications are probably best
based on components of biological variation, namely, on within-subject and betweenSLibject variation. This level is based on the thesis that we can produce general quality
specifications by seeking clinician input. Clinicians should be able to outline what
quality is required. This can be done by requesting clinicians to respond to a series of
short case studies, or vignettes, on the interpretation of test results, fhe responses are
then collated, differences calculated, frequency distribution of differences calculated,
median, 25'*^ and 75'’’ percentile of differences, Z-scores decided upon, faking
within-subject variability from published literature, the analytical performance
required to make this clinical decision at the desired level of probability can be
calculated. Use the median, 25‘*’ and the 75'*’ percentile of differences to create three
levels of quality specification: desirable, optimum and minimum.

Level 3: Quality specifications from professional recommendations
A small number of international and national professional expert groups have
proposed detailed quality specifications, examples of which include:
The National Cholesterol Education Panel in the U.S. published recommendations
for the precision, bias and total error allowable of lipid analysis.
•

The American Diabetes Association documented quality specifications for self
monitoring blood glucose systems"^^ and for glycated haemoglobin analyses.'^'^
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Rxpert groups from the National Academy of Clinical Biochemistry in the U.S.
proposed quality specifications for thyroid hormone assays, therapeutic drug
analyses, tests for monitoring diabetes mellitus and liver function tests.
A Ruropean Working Group has proposed quality specifications for use in the
evaluation of the precision, and bias of analytical systems, based on biological
variation."^"^
Another Ruropean Working Group has suggested quality specifications for
reference methods and for validating routine methods and for assigning values to
materials used in proficiency testing (PT) or external quality assessment scheme
(RQAS), based on biological variation.

Level 4: Quality specifications based on regulation and External Quality
Assessment (EQA)
A few countries have defined analytical performance standards that laboratories must
meet, in some cases to achieve/retain accredited status. The American Clinical
Laboratory Improvement Act of 1988 (CLIA’88) documents total error allowable for
a number of commonly assayed analytes. Similar legislation exists in Germany, but
the quality specifications are different.

Table 2. CLIA ‘88 Legislation for Quality Specifications for Acceptable
Performance^
Analyte

Acceptable Performance
(Total Error Allowable as Precision + Bias)

Albumin

Target value ± 10%

Alkaline Phosphatase

Target value ± 30%

ALT

Target value ± 20%

Calcium

Target value ± 0.5mmol/T.

Cholesterol

Target value ± 10%

Creatinine

Target value ± 15%
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A major disadvantage to these is that the figures are based on what is achievable
rather than what is desirable. However, more laboratory professionals are using fixed
limits as criteria of acceptability. These generally denote total eiTor allowable.
Some examples of CL IA ’88 Quality Specifications for Acceptable Performance are
outlined in the Table 2
Level 5: Quality specifications based on the state of the art
Data about what is actually achieved analytically are often available from PT and
EQAS organisers. However, the documented analytical performance may not truly
refiect the state of the art because samples circulated may not behave exactly like
patient samples, due to matrix effects. Performance achieved may bear no relationship
to actual medical needs.

2.7.4 Strategies for setting quality specifications based on biological variation
All strategies for setting quality specifications based on biological variation such as
precision, bias and total error allowable have advantages and disadvantages. The
fundamental principle is that they should be:
i.

firmly based upon medical requirements

ii.

usable in all laboratories irrespective of size, type or location

iii.

generated using simple to understand models, and

iv.

widely accepted as cogent by professionals in the field

2.7.5 Quality specifications for precision: calculating total variation
Precision (random variation) is defined as the closeness of agreement between
independent measurements obtained under stipulated conditions. In practice,
precision is measured by replicating analysis of the same sample in the internal
quality control programme. To decide how low the precision of an assay should be,
we must determine what effects precision has on test results and clinical decision
making. All analytes assayed in the clinical laboratory vary inherently due to
i.

pre-analytical variation

ii.

analytical variation and

iii.

within-subject variation
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These variations are all random and can be considered to have Gaussian distributions
where the dispersion can be described in terms ot'standard deviation (SD). If we
consider that the pre-analytical variation is negligible, analytical variation is called
SD,\, within-subject biological variation is called SDi then the total variation (SDt)
can be calculated as follows:
SDt^ = SDa^ + SDi^ or SD-i = (SDa^ + SD,^)''^
2x1/2
or CV| = (CVa^ + CV|^)

The effect of precision on test result variability'
If we ignore pre-analytical variation, test result variation is due to within-subject and
between-subject variation. As within-subject variation is constant, then the amount of
"analytical noise” added to our biological "signal” depends only on analytical
precision. We can calculate the effect of varying precision using the fomiula above.
If the analytical variation were exactly the same as the within-subject variation
(CVa - C'V,) then;
CV| =(CVa^

(2CV|-)''’= 1.414 CV,

which means that the intrinsic (due to biology) variation has increased by 41% due to
analysis. Similarly if precision were twice as large as within-subject variation (CVa =
2CV,) then
CV| = f(2CV|)^ + CVi^'’ = (4CVr + CV|^)= (5 CVf )= 2.236 CV,^

which means that the intrinsic variation by 123.6% due to analytical variation.
On the other hand, if analytical precision were only half as large as the within-subject
variation then
CV| =[(l/2CV|)^ + CVr|'- = (l/4CV|- + CVr)''^ =(5/4CV|- )'- = I.II8CV|^

which means that the intrinsic variation has increased by 11.8% due to analytical
variation, fhe relationship between the amount of variation added to true test result
variability to the ratio CVa/CVj is not linear. As precision increases the amount of
analytical "noise” added to the "biological signal” increases relatively more. Everworse precision gives ever-bigger dispersion.

Quality specifications for precision based on biological variation
fhe concept that analytical variation should be less than one-half the average withinsubject variation was developed 30 years ago. As seen above, this would add about
10% analytical "noise” to the "biological signal”. Therefore it is postulated that the
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best quality specification for precision is
Analytical precision < one-half the within-subject variation, or
CVa < 0.50CV,
This basic concept has been expanded and it has been proposed that:
Desirable performance is defined by CV^ < 0.50CVi. This formula is generally
applicable.

But, in order to cater to those analytes for which the general quality

specifications are too “loose” or too “stringent” then the following is suggested:
Optimum performance is defined by CV^ <0.25 CV|. The more stringent quality
specifications generated using this formula should be used for analytes for which
desirable performance standards are easily achieved with current technology and
methodology.
Minimum performance is defined by CV^ < 0.75 CV[.

The less-stringent quality

specifications generated using this formula should be used for those analytes for
which the desirable performance standards are not easily attainable with current
technology and methodology.
2.7.6 Quality specifications for bias based on biological v ariation
A positive bias will increase the percentage outside the upper reference limit and
decrease the percentage outside the lower reference limit. A negative bias will have
the same effect but on the opposite reference limit. From a medical point of view,
then, the fundamental concept is for laboratories throughout a homogenous population
area to use the same reference intervals. I low much bias can be allowed so that
reference intervals are transferable over geography and time?
fhe reference interval is made of within-subject biological variation (CVi) and
between-subject variation (CVc,). and if analytical precision is considered negligible,
this "group” biological variation can be calculated as simple addition of variances
(CVf +
For us all to use the same set of reference values, then, analytical bias should be less
than one-quarter the group biological variation, or
Ba < 0.250(CV|^ + eVo^)'’^
One can calculate that where Ba < 0.250(CV|" + CVg")’'\ then 1.4% are outside one
reference limit and 4.4% outside the other. Thus, less than 1% more (0.8%) of the
group are outside the reference interval than the 5% one would expect by definition.
The increase in numbers of people outside the reference interval is 0.8/5.0 = 16%,

34

which seems “reasonable” for a general quality specification.
One can also calculate that when Ba < 0.375(CV|“ + CVq")'then 1.0% are outside
one reference limit and 5.7% are outside the other so that about 1.7% more than the
desirable 5% are outside the reference interval (1.7/5.0 = 34% of people).
Where Ba < 0.125(CV|“ +

then 1.8% are outside one reference limit and

3.3% outside the other, so that 0.1% more than the desirable 5% are outside the
reference interval (0.1/5.0 = 2% of people).
This infers that, like precision, there should be three levels of quality specification for
bias;
Desirable performance is defined by Ba < 0.250(CVi^ + CVg")'^".

fhis is the

original, most widely accepted and very frequently used quality specification based on
biological variation, but it is suggested that, in order to cater for those analytes for
which the general quality specifications appear too “loose” or too “stringent” then:
Optimum performance is defined by Ba < 0.125(CVi“

CVg“)'^“,

this parameter is

used for analytes where desirable performance is easily achieved with current
technology and methodology.
Minimum performance is defined by B A < ().375(CV|" + CV(i")''“, and may be used
for analytes where desirable performance is not attainable with current technology
and methodology.
2.7.7 Quality specifications for total error allow able based on biological variation
Since the general desirable quality specifications are
CVa<0.50CVi
BA< 0.250(CVr ^CVg“)‘^-

fhen the desirable quality specification for total allowable error (formula derived
earlier) is
TG < 1.65(0.50CV|) ^ 0.250(C'V|- ^ CVq-)''’
The "three-level model” allows for analytes that cannot meet these general quality
specifications using current technology and methodology.
Thus the minimum quality specification for total error allowable is
Tf-;a< 1.65(0.75CV|)

0.375(CVr ^ CVo’)''’

On the other hand, analytes that can easily meet general quality specifications with
current methodology and technology the optimum quality specification error
allowable is:

TE, < 1.65(0.25CV,)

0.125(CVf

CVg")''"
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2.7.8 Other quality specifications based on biological variation
A mathematical model based on investigating significant changes in serial results has
shown that quality specifications can be set for allowable difference between two
methods used to analyse the same analyte in the a single laboratory as
allowable difference < 0.33 CV| For many analytes, this level of performance is
attainable. A Working Group of the European EQAS Organisers Group has
investigated objective means to set quality specifications for application as the fixed
limits of acceptance in P'f and EQAS.
Allowable error < 0.25()(CV|^ + CVo’)''- +2.33(().50CV|).
A simple way to assess whether analytical techniques meet quality specifications is
through calculating what is termed Critical Systematic Error (abbreviated as z\SEc)
ASE,-[(TEa-BA)/CVAl-1.65
ASEe indicates, in a single statistic, the number of SD the mean can shift before

exceeding the total error allowable quality specification, fherefore, ASEc -^10 equates
to a method where the mean can shift 10 SDD before exceeding the quality
specifications, whereas ASEc

2 indicates the mean can only shift 2SD.

A method with a high :\SEc (>3.0) will easily meet requirements for quality and could
be managed in routine service with simple quality control.

A method with

intennediate ASEc (2.0-3.0) provides the desired quality when everything is working
correctly but would require more control samples per run or more stringent rules for
acceptance or rejection. A method with low ASEc (<2.0) will be very difficult to
manage in routine practice and may be unacceptable for routine service.

2.8 Index of Individuality
The individuality of an analyte is determined by calculating the index of individuality.,
usually abbreviated to II. This idea came from Eugene Harris, who suggested that we
could calculate the index of individuality as the ratio of the total within-subject
variation to between-subject biological variation - formally as
ii =

[cv,\‘ + cvri' - / evu''*

This is most often simplified to
CV,/CVo
which is satisfactory if CVa < CV; which it often is with current methodology and
technology. 44
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A low index of individuality means that the analyte has marked individuality whereas
a high index of individuality means that the analyte has little individuality
Table 3. Some examples of the Index of Individuality 44

VVithin-subject

Between-subject

Index of

Variation (%)

Variation (%)

Individuality (II)

ALT'

24.3

41.6

0.58

Albumin

3.1

4.2

0.74

Aik Phos

32.6

39.0

0.84

Calcium

1.9

2.8

0.68

Cholesterol

6.0

15.2

0.40

Creatinine

4.3

12.9

0.33

Analyte

The individuality of analytes significantly inlluences reference values. For creatinine,
individuals could have values that are very unusual for them but these clinically
important results would still lie within the conventional reference interval. When II is
low, particularly when less than 0.6 the dispersion of values for any individual will
span only a small part of the reference interval. Reference values will be of little
utility, particularly for deciding if change has occurred. For analytes with marked
individuality, comparison with previous values has many advantages. In contrast
when II is high, particularly when it is higher than 1.4, the distribution of values from
a singe individual will cover much of the entire distribution of the reference interval.
Thus, conventional reference values will be of significant value in many clinical
settings. However, very few analytes have an index of individuality greater than 1.4;
in many, II is less than 0.6. Therefore, population-based reference values are not
good guides as to whether changes have occurred.
One can increase II by stratification, thereby making reference values more useful.
Stratification according to sex can vastly increase the utility of conventional
population-based reference values.
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2.9 Quality Standardisation
With three exceptions (glucose, cholesterol and llbAlc), there are no guidelines that
manufacturers meet specific standards of accuracy and reproducibility. As
proficiency testing schemes shows, there are large discrepancies among the various
methods used to measure the same analyte solutions.^*^ These variances indicate a
need for accuracy and analytical standardisation. Standardisation would mean that
analytical measures are directly comparable to each other. Specifically, measures
would be directly related to National Institute for Standards and Technology (NIST)
or other similar standards. Examples of work being done to achieve standardisation in
a geographical region include the following studies in Japan and in the Nordic
countries.

In the ITikuoka Prefecture in Japan, with a population of 5 million, the Prefecture
Medical Association, Medical Technologists’ Association, and the Association of
Five I lospitals have established a project for the standardization of laboratory data. 50
As a result, inter-institution variation has decreased mainly in clinical chemistry
measurements, accomplishing the primary aim of the project. In the future, they will
continue their efforts to increase the number of measured analytes and expand the
area for this standardisation project.

In the Nordic Reference Interval Project (NORIP), reference intervals were
established for 25 common biochemical quantities.'* In the project, samples from
more than 3000 reference individuals collected in the 102 participating laboratories
from all five Nordic countries were analysed locally. In order to maintain a high level
of analytical quality and to document this quality, a common calibrator/reference
preparation (CAL) and a number of control samples were analysed together with the
reference samples. The CAL was used to harmonise the many different analytical
procedures and calibrations by simple recalibration factor T/M where T is the target
value based on reference methods and M is the mean of 10 replicate measurements of
CAL in each laboratory. The analytical quality specifications (analytical goals) were
based on specifications created directly for the purpose of sharing common reference
intervals and only the bias criteria were used because bias is the dominating problem
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in the transfer of reference intervals. An interesting outcome was that it was only for
the biologically well-regulated quantities, serum sodium and serum calcium, that the
selection of the best laboratories gave considerably narrower reference intervals.
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3.0 Objectives
This project set out to:
i.

To verify the reference ranges quoted in the Clinical Biochemistry
Department, Cork University Hospital (CUH), by using samples from blood
donors at the local blood bank.

11.

fo study the statistics of the adult population served by the laboratory over a
one-month period.

111.

fo investigate the quality of the results from the CUH Biochemistry
Department.
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4.0 Materials and Methods

4.1 Materials
4.1.1 Instrumentation

Olympus 5400 Analyser
The Olympus AU5400 Automated Chemistry Analyser is a system which optically
measures the components of serum, urine and CSF. It automates the main processes
such as serum dispensing, reagent dispensing, mixing and photometry.
It is a modular system and consists of 3 analyser units that are connected via a
tracking system.
Unit 1 contains the 1ST unit and consists of two sets of electrodes known as cells,
fhe three units have identical reagent profiles (general chemistries) with the
exception of direct bilirubin which is only on unit 1 and lithium which is only on unit
2. fhese reagent profiles can be changed. Chemistries can be set up on either or both
the inner and outer rings.
This analyser is the main analyser employed for non-urgent routine chemistries in the
Department of Clinical Biochemistry, Cork University Hospital (CUH).
Olympus 640 Analyser
The Olympus AU64() Automated Chemistry .Analyser is a system for analysing

the

components of serum, urine and CSF. It is a single unit analyser which uses the same
mode of operation as the Olympus .AU5400 described above.
This analyser is used primarily for urgent routine chemistry samples in the
Department of Clinical Biochemistry, Cork University Hospital (CUH).

4.1.2 Reagents
.Apart from the calcium reagent which was supplied by Roche, and the LDL being a
calculated parameter all reagents were acquired from Olympus Diagnostica,
O’Calkmhan Mills, Co Clare.
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4.2 Methods
4.2.1 Individual Analyte Assays
A brief outline of the principle of each individual assays is presented. Percentage
coefficient of variation (%CV) for the internal quality controls, Beckman Triad 2 and
Triad 3, were collected for a one-month period, and the mean of the 2 CVs (to two
decimal places) is given in brackets for each assay.

Albumin
Principle:
This assay procedure is based on the high affinity binding of albumin to Bromocresol
puiple (BCP) at pH 5.5.
BCPAlbumin

BCP Albumin complex

Yellow BCP dye turns green when complexed with album.in. Absorbance of this
green complex is measured at 600nm.
Ref. Olympus Albumin K.it Insert, OAR 6908, rev no. 02.
(CV=0.95%)

.Alkaline Phosphatase (Al-P)
Principle:
Alkaline phosphatase activity is determined by measuring the rate of conversion of pnitro-phenylphosphate (pNPP) in the presence of 2-amino-2-methyl-l-propanol
(AMP) to p-nitrophenol at pH 10.4

ALP

PNPP ^ AiVIP

>

pi\P-AMP-P04

The rate of change in absorbance due to the formation of pNP is measured
bichromatically at 410 /480 nm and is directly proportional to the ALP activity in the
sample.
Ref. Olympus Alkaline Phosphatase kit insert OSR6104.CE02, 11.03.2004.
{CV-1.55%)
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Alanine Aminotransferase (ALT)
Principle:
The method is based on the recommendations of the IFCC. ALT transfers the amino
group from alanine to 2-oxoglutarate to form glutamate and pyruvate.

The pyruvate

enters a lactate dehydrogenase (LDH) catalysed reaction with NADH to produce
lactate and NAD\ The decrease in absorbance due to the consumption of NADfl is
measured at 340 nm and is proportional to the AIT activity in the sample.
ALT

2-Oxoglutarate

L-Alanine

-----------------^

l.-Glutamate + Pyruvate

,011

I.-Lactate + NAD

Pvruvate ^ NADH ^ H'

Ref. Olympus System Reagent ALff kit insert OSR6107.CTT4. 04.03.2005.
(CV-0.85%

Amylase
Principle;
1 he

a-Amylase

assay

employs

4.6-ethylidene(Cj7)-p-nitrophenyi(Cj|)-

aj)-

maltoheptoheptaoside (ethylidene- O7 PNP) as substrate. Phis substrate reacts with aAmylase and a-Glucosidase to give a 100% release of p-Nitrophenol (pNP).

fhe

increase of absorbance per minute at 410 nm is directly proportional to the a-Amylase
concentration in the sample.

Method based on the recommendations of the

International Federation of Clinical C’hemistry (IFCC ).

(x-amylase
5 ethylidene- G7 PNP ^5 H2O
2 ethylidene-G5 + 2 G2PNP

-----------------------------------------------------------►

2 ethylidene-G42 G3PNP

ethylidene- (13-^ G4PNP

a-glucosidase
2 G2PNP + 2 G3PNP - 2 G4PNP ^ 14 FLO-

(PNP

-► 5pNP + 14G

p^nitrophenol; G = glucose)

Ref.: Olympus System Reagent for Amylase Kit Insert. OSR6182.CE03 24'*' Feb. ’04.
(CV= 1.26%)
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Aspartate Aminotransferase (AST)
Principle:
This method is based on the recommendations of the IFCC.

AST catalyses the

transamination of aspartate to 2-oxoglutarate, forming L-glutamate and oxalacetate.
The oxalacetate is reduced to L-malate by malate dehydrogenase (MDH), while
NADU is simultaneously converted to NAD". The decrease in absorbance due to the
consumption of NADU is measured at 340 nm and is proportional to the AST activity
in the sample.
AST

2-Oxoglutarate + L-Aspartate --------------------- ^

L-Glutamate -t- Oxalacetate

V![)U

Oxalacetate + NADII t H

L-Malate + NAD^

Ref. Olympus System Reagent AST kit insert OSR6109CE()4, 02/11/04.
(No % CV available, as the assay was not used in the one-month study)

Calcium
Principle:
C/alcium ions react with Arsena/o III in an acid medium to form a purple coloured
complex. The absorbance of this complex at 650 nm is proportional to the calcium
concentration in the sample.
Ref: Roche Calcium reagent insert. 1999-06-18623 16001
(CV= 1.16%)

Chloride
Principle :
Chloride is measured by an ion selective electrode (ISE). The ion selective electrode
produces an electromotive force according to the ion activity in aqueous solution. The
Chloride electrode on the Olympus has a molecular oriented membrane. (Ref. p H-35
Olympus AU640 users guide).
Ref: OLYMPUS AU640 Users Guide
(CV-0.37%)
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Cholesterol
Principle:
Cholesterol is determined after enzymatic hydrolysis and oxidation.

The indicator

quinoneimine is formed from hydrogen peroxide and 4-aminoantipyrine in the
presence of phenol and peroxidase. The reaction is as follows:
CUE

Cholesterolester + H2O

----------------- ►

Cholesterol + Fatty Acid

cno

Cholesterol

Cholestene-3-one +
POD

Quinoneimine

2H2()2 + 4-Aminoantipyrene + Phenol

Reference: Olympus System Reagent C’holesterol Kit Insert, GSR 6116.CE02 9'*^ Dec
2003.
(CV= 0.68%)

Creatine Kinase (CK)
Principle:
This method is based on the recommendations of the IFCC and the FXXT.S. CK
reversibly catalyses the transfer of a phosphate group from creatine phosphate to
adenosine diphosphate (A[)P) to give creatine and adenosine triphosphate (AfP) as
products.

I'he .A fP is used to produce glucose-6-phosphate (C16P) and ADP from

glucose. This reaction is catalysed by hexokinase (HK). The G6P is oxidised by the
action of the enzyme glucose-6-phosphate dehydrogenase with simultaneous
reduction of the coenzyme nicotinamide adenine dinucleotide (NADP) to give
NADPH and 6-phosphogluconate. fhe rate of increase of absorbance at 340/660 nm
due to the formation of NADPH is directly proportional to the activity of C'K in the
sample.

ck

Creatine Phosphate + ADP

^

Creatine + A fP

HE

ATP r Glucose

ADP -r Glucose-6-phosphate
G-6-PD

Glucose-6-phosphate -r NADP"^

-► 6-Phosphogluconate + NADPH -e H'

Reference: Olympus System Reagent for Creatine Kinase Kit Insert, OSR61 79.CE02,
29.05.04. No % CV available, as the assay was not used in the one-month study.
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Creatinine
Principle;
Creatinine forms a yellow-orange coloured compound with picric acid in the presence
of an alkaline solution. The concentration of this compound indicates the creatinine
concentration in the sample.
Creatinine + Picric Acid

^

Creatinine picrate complex

Reference; Olympus System Reagent Creatinine kit insert OSR6178.CE05,
27.05.2004
(CV= 1.71%)

Gamma (ilutamyltransferase (GGT)
Principle;
I'he test is based on the recommendations ol'the IFCC. GOT catalyses the transfer of
the gamma-glutamyl group from the substrate, gamma-glutamyl-3-carboxy-4nitroanilide. to glycylglycine. yielding 5-amino-2-nitrobenzoate.

L-Y-Glutamyi-3-carboxy-4-nitroanilide
+ Glycylglycine

y-G'f

L-y-Glutamylglycylglycine

------------- ^

+ 5-Amino-2-nitrobenzoate

Reference; Olympus System Reagent for Gamma Gf Rit Insert OSR6120.CB06
04.03.05
(CV= 1.23%)
High Density Lipoprotein Cholesterol (Hl)L)
Principle;
Anti human-[)-lipoprotein antibody in Reagent 1 binds to lipoproteins other than HDL
(LDL, VL.DL and chylomicrons), fhe antigen-antibody complexes formed block
enzyme reactions when Reagent 2 is added.
HDl.-Cholesterol is quantified by the presence of an enzyme chromogen system this
is measured at 600nm.
Aiiti-lmman-ii-Lipoprotein

LDL, VI.DI. and chylomicrons

Antigen-Antibody complexes
Antibodv
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Cl

I IDL-Cholesterol + M2O + O2

11: and Clio

------------- ►

Chulest-4-en-one + l^atty Acids

I2O2

POD

Ib07 + 4-AA + F-DA0S

Reference:

Olympus

System

Blue dye + 2 II2O

Reagent

for

flDL-Cholesterol

Kit

Insert,

OSR6187.CE()7.291004
(CV= 0.87%)

Iron
Principle:

1-^e'" is reduced to Fe“\ which forms a blue complex with TPTZ {2,4,6-Tri [2pyridyl]-5-triazine). Fhis complex shows a maximum absorption at 590 nm. dhe
intensity of the formed colour is proportional to the iron concentration in the sample.
Reference: Olympus System Reagent for Iron Kit Insert, OSR6186.CF02. 04.02.04
(No % CV available - omission)

Potassium
Principle:

Potassium is measured by an Ion Selective Fdeclrode. I'he ion selective electrode
produces an electromotive force aceording to the ion activity in aqueous solution.
Calibrator potentials are determined and the A E / A log concentration is stored in the
microprocessor memory as a factor for calculating unknown concentration when E of
the unknown is measured, fhe Potassium electrode on the Olympus has a crown ether
membrane
Ref. p fI-35 Olympus AU640 users guide, Olympus ISE Reagents/Standards inserts
sheet OL66320.CE01 3^^ Sep ■()3
(CV= 0.70%)
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Sodium
Principle:

Sodium is measured by an Ion Selective Electrode. The ion selective membrane
produces an electromotive force according to the ion activity in aqueous solution
On the Olympus analysers the sodium electrode has a crown ether membrane.
Ref. p M-35 Olympus Ali640 users guide, Olympus ISE Reagents/Standards inserts
sheet OL66320.CE()1 3"' Sep '03
(CV=0.33%)

Total Bilirubin
Principle:

Bilirubin in serum or plasma when mixed with blanking reagent absorbs light at 450470 nm with secondary readings at 600-660 nm. The addition of Ferricyanide ions
oxidise the bilirubin to biliverdin. The difference in absorption is measured using the
analyser’s self-blanking facility and is proportional to the concentration of bilirubin in
the sample.
I'crricyanide
Bilirubin
(yellow)

►

FTliverdin
(green)

Ref Olympus System Reagent for Fotal fblirubin Kit Insert, OAR 6181 issued
August 2004 Rev No. 02
(CV= 0.67%)

Total Protein
Principle:

Cupric ions react with protein in alkaline solution to form a purple complex. The
absorbance of this complex is proportional to the protein concentration in the sample.
Ref Olympus System Reagent for Total Protein Kit Insert, OSR 6132.CE()4,
08/09/2004
(CV= 1.56%)
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T riglycc rides
Principle:
The triglycerides are determined after enzymatic hydrolysis with lipases. The
indicator is a quinoncimine formed from hydrogen peroxide, 4-aminoantipyrine and
4-chlorophenol under the catalytic influence of peroxidase. The absorbance change,
measured at 52()nm, is proportional to the triglyceride concentration in the sample.

Lipase
Triglyceride

Glycerol ^ Fatty Acids
GK

Cdycerol

ATP

Glycerol-3-phosphate + ADP
GPO

Cjlycerol-3-phosphate

O2

Dihydroxyacetonephosphate
ILO.

211202 ^ 4- Aminoantipyrine
- 4-('hlorphenol

POD
----------------- ^

Quinoncimine ^ HCL + 4H2O

Ref: Olympus System Reagent for Friglyceride Kit Insert, OSR6133.CT02. 26'*’ Nov
*03.
(CV= 0.72%)

Urate
Principle:
Determination of uric acid by reaction with uricase. I'he formed H2O2 reacts with 3,5dichloro-2-hydroxybenzenesulfonic acid and 4-aminophenazone to give a red-violet
quinoncimine as indicator.

The absorbance change, measured at 520nm, is

proportional to the uric acid concentration in the sample.
Uricase
Uric acid ^ O7 ^ 21 TO

---------------------- ►

Allantoin + CO^

FLO^
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Peroxidase
N-(4 antipyryl)-3-ehloro-5-

2H2O2 + 3,5-diehloro-2
-hyroxybenzenesLilphonic aeid

sulphonate-p-benzoquinonemonoimine

^ 4-Aminophenazone

IICL + 4H?0

Ref; Olympus System Reagent for Uric Acid Kit Insert, OSR6136.CE01 16'*^ July ’03.
(CV- 0.99%)

Urea
Principle:
Urea is hydrolysed in the presence of water and urease to produce ammonia and
carbon dioxide, fhe ammonia produced in the first reaction combines with 2oxoglutarate and NAUII in the presence of glutamate-dehydrogenase to yield
glutamate and NAD2 fhe decrease in NADU absorbance per unit time, measured at
340nm, is proportional to the urea concentration.

U rease

Urea +■ 21 DO-----------------------------------------------► 2NII4' + CO.r'
2-()xoglutarate t 2NIl4^

2NADI1----------^ 2 L-Glutamate + 2NAD f 2U2O

Ref: Olympus System Reagent for Urea Kit Insert, OSR6134.CE02, 04/04/2004.
(CV= 1.69%)

Low Density Lipoprotein (LDL)
Principle;
LDL cholesterol is a calculated result. The Triglyceride result is divided by 2.17.
giving the VLDL result. IlDL and VTDL are combined and this value is subtracted
from the total cholesterol result, yielding the LDL result
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4.2.2 Software
Cognos Impromtu
Impromptu ties all of database aceess procedures to an Impromptu file called a
catalog to simplify the interaction with the corporate database.

Catalogs contain

pointers to the data, not the data itself, fhe data resides in the database, and when a
report is run, a catalog must be opened.

One can isolate specific data from the

database and naiTow the focus of the information that appears on the report using its
filter feature. The information can then be sorted in the report to organise how the
data is presented. Grouping of data can lead to a more meaningful report.

Analyse-it
’'Analysc-it” is a statistical tool for Microsoft Hxcel.

”Analyse-it” Clinical

L.aboratory provides extensive tools for evaluating the performance of a methodology
and its diagnostic performance.

It includes over 30 parametric & non-parametric

statistics, including descriptive statistics, box-whisker plots, correlation, multiple
linear regression analysis, ANOVA. & chi-square statistics for general statistical
research. A separate statistical software package is available for clinical method
evaluation, providing NCCLS and IfCC' procedures for accuracy, imprecision,
linearity and diagnostic testing.

Graph Pad Prism
GraphPad Prismis a registered trademark of GraphPad Software, Inc. It helps to
create scientific graphs, fit curves, perform statistical analyses, and organise
experimental data. Hach Prism project file is divided into five sections; Data tables.
Info, Results, Graphs, and Layouts. Sections contain pages known as sheets, each
holding an individual graph, table etc. Prism remembers all logical links between
sheets. All related sheets are shown in boldface in the navigator. The programme
was set up to use the lower and upper limits as two grouping variables for each graph.
Rectangles were then drawn from the upper to the lower points on the graph for all
groups of subjects. Hach rectangle was then coloured using the colour code - blue for
the CIJH quoted reference range, green for GP samples and red for hospitalised
patients. Hach set of analyte reference intervals was subdivided into separate sexes for
graph clarity.
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5.0 Results
5.1: A Study of Blood Bank Samples
The first part of this project set out to verify the reference ranges quoted in reports of
results from the CUH Biochemistry Department. Permission was sought and granted
from the CUII Ethics Committee and the Irish Blood Transfusion Board (IB I S) Cork,
to use annonymised blood bank donor samples. 120 samples of blood from male
blood donors and 120 samples from female blood donors were collected from the
IBTS (Cork). These samples were analysed for 21 routine chemistry analytes on the
Olympus AIJ 5400.
The results were:
i.

viewed on the laboratory information system (MS) - APEX

ii.

viewed on statistical graphics from the Olympus AU5400 analyser

iii.

entered into an excel file and presented to a statistical software programme
called “Analyse-it”"^'^

For each analyte in each group the information processed included:

i.

N o n - pa r a me tr i c r e fe r e n c e
interval

ii.

Frequency histogram

iii.

Box-Whisper plot

i V.

Normal Quantile plot

V.

vi.

*»

xiv.
XV.

xvi.

vii.

95% Confidence Interval

viii.

Variance

IQR
Percentiles - 25'*', 50"^ and
75"^

xvii.

n

Mean

Range

Coefficient and “p” values
for skewness

xviii.

Coefficient and ”p” values
for kurtosis

xix.

3 Normality test results of

ix.

SD

Coefficient and “p” value:

X.

SE

Anderson-Darling,

xi.

CV

Kolmogorov-Smirnov

xii.

Median

Shapiro-Wilk

xiii.

96.5% Confidence Interval
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The interquartile range (IQR) is defined as the 75‘'^ percentile result minus the 25'^
percentile result i.e. the central 50% range of the results/^ A near outlier is defined as
a result which is between 1.5 and 3.0 IQRs away from the upper and lower quantiles.
A far outlier is defined as a result which is more than 3 IQRs away from the upper and
lower quantiles.
Figure 4 below shows an example of the distribution of one of the analyte values,
.Male ALT, before outliers were removed. The figure shows three forms of graphing
of the same data. The top (figure 4a) shows a histogram. Figure 4b shows a BoxWhisper plot and the figure 4c shows the normal quantile graph. The X axis shows the
AL.T value.
Figure 5 shows an example of the same distribution of Male ALT values after outliers
were removed. Similar data on all analytes in this study were processed and saved.
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(a)
n

120

Mean
95% Cl

29.033
26.497

Variance
SD
SE
CV

196.9064

Median
96.5% Cl

27.000
24.000

Range
IQR

82
13.25

to 31.570

14.0323
1.2810
48%

(b)
to 29.000

Percentile
2.5th
25th
50th
75th
97.5th

12.025
19.750
27.000
33.000
81.800

(C)

Coefficient
Anderson-Darling
Skewness
Kurtosis

4.9313
2.1864
6.6264

P
<0.0001
<0.0001
<0.0001

ALTUL

Figure 4. Graphical representation of distribution of Male blood donor ALT values before
outliers were removed in 3 forms: (a) Histogram, (b) Box-Whisper, and (c) Quantile.
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(a)
112
(8 outliers

n
Mean
95% Cl

26.241
24.64 to
27.84

Variance
SD
SE
CV

72.9414
8.5406
0.8070
33%

removed)

(b)
Median
95.3% Cl
Range
IQR
Percentile
2.5th
25th
50th
75th
97.5th

26.000
23.00 to
28.00
37
13

11.825
19.000
26.000
32.000
45.000

(C)

AndersonDarling
Skewness
Kurtosis

Coefficient

P

1.0710
0.4474
-0.4470

0.0082
0.0518
0.2700

Figure 5. Graphical Representations of Male Blood Donor ALT Values Distribution after
Outliers were Removed, in 3 forms: (a) Histogram,(b) Box-Whisper, and (c)Quantile
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5.1.1 Male Blood Donor Results
The resulting non-parametric 95% eonfidence intervals for all analytes, for the male
blood donors are outlined in Table 4 below.

Table 4. Analysis of Reference Interval Results of 120 Male Blood Donors
Analyte
Albumin

CUH
Quoted
Ref Range
36-44

Blood Bank Males
95% CL Ref Intervals
(n = 120)
39-49

35-110

53-122

4-45

12-82

28-100

26-96

6-42

18-46

2.10-2.62

2.19-2.54

3.5-5.0

3.6-7.7

95-107

98-104

40-180

81-598

50-130

79-133

6-48

15-102

1.0- 1.7

0.77-1.97

9-28

7.0-27.7

220-450

285-485

0.70-1.00

0.81-1.03

0.80-1.50

0.98-1.76

132-144

139-146

2-20

3-24

62-82

69-83

2.5-7.0

3.8-9.2

212-482

216-471

(g/L)

ALP
(IVL)

ALT
(U/L)

Amylase
(l!/L)

AST
(I'/L)

Calcium
(inmol/L)

Cholesterol
(minol/l.)

Chloride
(inmol/L)

CK
(U/L)
Creatinine
(fimol/L)

GOT
(l /L )
HDL
(mmol/L)

Iron
(fiinol/L)

LDH
(U/L)
Magnesium
(mmol/L)

Phosphate
(inmol/L)

Sodium
(mmol/L)

Tot. Bilirubin
(nmol/L)

Tot. Protein
(g/i)

Urea
(mmol/1,)

Urate
(^mol/L)

56

the cut! reference As can be seen from the table, there were only four 95% reference
intervals for the 120 male blood bank donors that were enclosed in the CUM quoted
reference ranges, i.e., amylase, calcium, chloride and urate.
Some interesting notes from the results of male blood donor samples follow;
66.2% had Cholesterol results outside the CUM desired range; 80 subjects had
a cholesterol >5.05 mmol/L
II.

iii.

59.1% had Albumin results outside the CUM reference range
58.8% had CK. results outside the CUM reference range; 70 subjects had CK
>164 U/L (one male subject had a CK. of 745 Li/L)

IV

33.4% had urea results outside the CUM reference range; 40 subjects had urea
results > 6.8mmol/L
23.5 % had vSodium results outside the CUM reference range; 28 subjects had a
sodium result >144 mmol/I.

VI.

vii.

20.8% had phosphate results outside the CUM reference range
15% had MDL results outside the CUM reference range; 8 subjects had a MDL
< 0.87mmol/L and 10 subjects had a IIDL > 1.67 mmol/L

Vlll.

11.7% had Gamma G f results outside the CUM reference range; 1 subject had
a result of 310 U/L

IX.

10.8% had Al/f results outside the CUM reference range; 13 subjects had an
AL r>43 U/L
9.5% males had Iron results outside the CUM reference range; 15 subjects <
9.9 umol/L
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5.1.2 Female Blood Donor Results

Results of analysis of the samples from 120 female blood donors are presented in
Table 5.

Table 5. Analysis of Reference Intervals Results of 120 Female Blood Donors

Analyte

CUH Ref Range

Albumin

36-44

Blood Bank Females
95% CL Ref Intervals
(n= 120)
36-49

35-110

43-116

4-45

8-37

28 - 100

28.9-97.9

6-42

14.0-42.9

2.10-2.62

2.14-2.53

3.5 - 5.0

3.61 - 7.50

95-107

99 - 106

40- 180

47 - 339

50 - 130

64.0- 113.8

6-48

10.0-75.7

0.9 - 2.2

1.00-2.15

9-28

5.4 - 25.2

220 - 450

234 - 500

0.70- 1.00

0.77 - 0.99

0.80-1.50

1.01 - 1.77

132 - 144

139- 147

2-20

3.0-16.0

62-82

67 - 85.9

2.5-7.0

3.0 - 8.0

212-482

166-390

(g/i)

ALP
(U/L)

ALT
(li/L)

Amylase
(n/L)

AST
(l/L)

Calcium
(mmol/l,)

Cholesterol
(mmol/I.)

Chloride
(mmol/L)

CK
(UAL)
Creatinine
(^mol/L)

GGT
(U/L )

HDL
(mmol/L)

Iron
(fimol/L)

LDH
(F/L)
Magnesium
(mmol/L)

Phosphate
(mmol/L)

Sodium
(mmol/L)

Tot. Bilirubin
(fimol/L)

Tot. Protein
(g/L)

Urea
(mmol/L)

Urate
(fimol/L)
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In the case of the female subjects, the resulting 95% reference intervals of 8 of the 21
analytes were included in the CIJH reference ranges. These were ALT, amylase,
calcium, chloride, creatinine, HDL, magnesium and total bilirubin.
Some interesting aspects of the results of the female reference interval include:
i.

51.7% females had cholesterol results >5.0 mmol/L

ii.

34.2% had phosphate results outside the quoted range (2 subjects had
phosphate <0.8 mmol/L and 29 > L50mmol/L0

iii.

27.4% had iron results < 9 pmol/L (33 subjects)

iv.

23.4% had sodium results > 144 mmol/L (28 subjects)

V.

vi.

23.2% had CK results >140 U/L (1 subject had a result of 954 U/L)
18.4% had albumin results > 44g/L

Conclusion
Lhere were many discrepancies between the resultant non-parametric 95% confidence
reference intervals generated by these results and the CUH quoted reference ranges.
It is likely that pre-analytical factors which were outside the control of this study
contributed to these discrepancies. These included:
i.

the method of blood collection. Samples were taken from donated blood,
which entailed longer venepuncture and subjects being supine for longer than
routine blood sampling.

ii.

aliquots from blood donated in the evening had been centrifuged the following
day. These conditions do not mirror the pre-analytical conditions under which
samples an’iving on a daily basis to the CUlI Biochemistry laboratory are
acquired.

iii.

results for some subjects would indicate that underlying disease may have
been present.

Also, it is worth noting that according to NCCLS guideline, when an outlier is
removed, another sample should replace it so that the minimum number is still 120. It
was not possible to do this at the time of this study. Therefore, at this stage, it was
decided to implement a different method of verification.
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5.2: Retrospective Study of Patient Data
In the second part of this project, the software programme COGNOS was used to
collect and sort the data for all weekday results for the chosen analytes over a onemonth period for each of the age groups 18-45, 46 to 70, and over 70 (these were an
intuitive set of groupings). To improve the significance of the ranges, each age-group
was further divided by sex and origin of sample (either GP surgery or hospital). IFCC
reference ranges were established using a computer programme for each of the
subgroups (17 in total) for all of the 19 analytes.

Each range was checked for

Normality by 3 different formulae - Kolmogorov-Smirnov, Anderson-Darling and
Shapiro-Wilk. Weekday daily means for the following 19 analytes were gathered:

1. .Albumin
2 AEP

1 1. Iron

3. Ai;r

13. Potassium

4. Amylase

14. Sodium

5. Calcium

15. Total Bilirubin

6. Cholesterol

16. fotal Protein

7. Chloride

17. Triglycerides

8. Creatinine

18. Urate

9. GGT

19. Urea

12. I.DL

10. IIDL

Daily statistics for internal quality controls (IQC), Beckmi
the period of the study were analysed. An external quality
for UK NEQAS for Clinical Chemistry was also included in the study.
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Patient samples for each analyte daily mean were divided into the following
categories:

1. All GP Patients

10. Females aged between 46 and 70 from
GPs

2. All GP Females
3. All GP Males

11. Females aged between 46 and 70 in

4. All I lospitalised Females
5. All Hospitalised Males

hospital
12. Vlales aged between 46 and 70 from

6. Females aged between 18 and 45
from GPs

GPs
13. Males aged between 46 and 70 in

7. Females aged between 18 and 45 in
hospital
8. Males aged between 18 and 45 from
GPs
9. Males aged between 18 and 45 in

hospital
14. Females over 70 from GPs
15. Females over 70 in hospital
16. Males over 70 from GPs
17. N/Iales over 70 in hospital

hospital

There were 21 weekdays in .May 2005. The study involved 19 analytes for 19
subgroups (17 patient groups and two IQC). This resulted in 7,581 means being
evaluated. Fach separate group of means for those 17 sets of individuals, for each
analyte, was analysed. The first objective was to establish a reference interval for each
set of means. The mean was calculated as a parametric analysis since the means
displayed Gaussian distribution. The second objective was to construct a continuous
summary descriptive for each set. Phis included:
1. Frequency Histogram, Mean, 95% Confidence Limit (CL), Standard Deviation
(SD), Standard Fforor (SF), Coefficient of Variation (CV).
2. Median, 95.5% CL, Range, Inter-Quailile Range (IQR), 0.5'^\ 25''\50‘'\75''^ and
99.5''^ value with a Box Whisper plot.
3. Graph of scatter around the normal quartile, tests for normality, skewness and
kurtosis (coefficients and p values). Normality was tested 3 times, using different
formulae, Shapiro-Wilk, Anderson-Darling and Kolmogorov-Smirnov.
The programme was run 4 times for each group i.e., 17 groups, for all 19 analytes 1,292 times in total. Graphics and results of all were processed. Statistical

information from the software used was transcribed manually into an Excel file
(Mean, SI), and CV). CVs from the IQC gave an indication of the scatter due to the
methodology, fhe simplest technique (standard normal deviate test) to decide if
stratification is necessary is that advocated by Sinton and co-workers■^^ which states
that if the mean of a potential subset of the population differs by more than 25% of
the 95% reference interval for that analyte, then that group warrants separate
stratification. On this basis, the 25% value of the CUH quoted range was calculated
for each analyte.

Re.sults of the Retrospective Patient Data Study
The data is presented in a table form for each analyte. In order to visualise the
resulting ranges, the information was further separated by sex and each set of results
entered into a graphics programme'^'^. Different colours were used for the three
categories of ranges - blue for the CUH quoted reference range, (ireen for OP
patients and red for hospitalised patients. Of all the groups studied, the subgroup “All
GP” subjects is the most likely to encompass “healthy” individuals, fhese reference
intervals are highlighted in green for easy comparison with the quoted ranges highlighted in blue.
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ALBUMIN

Table 6. Number, Reference Interval and Means for ALBUMIN

Number ‘*n”

CUH Quoted Reference Range

Reference Interval
g/L

Mean
g/L
40
38.1

Olympus AU 5400 May ’05 Interval

22686

36-44
(25% of range = 2)
35.8 - 40.4

Olympus AU 640 May '05 Interval

878

30.4 -35.9

33.2

All from GPs

13394

40.3-42.1

41.2

All Females from GPs

7767

39.9-41.6

40.7

All Males from GPs

5431

40.7- 42.9

41.8

All Hospitalised Females

8353

32.3 - 34.7

33.5

All Hospitalised Males

4121

31.5-35.1

33.5

Females aged 18 to 45 from GPs

2481

40.4 -42.5

41.5

Hospitalised Females aged 1 8 to 45

1818

34.9 - 38.5

36.7

Males aged 1 8 to 45 from GPs

1507

42.5 -45.5

44.0

Hospitalised Males aged 18 to 45

903

34.8 - 39.3

37.0

Females aged 46 to 70 from GPs

2817

39.9-41.9

40.9

Hospitalised Females aged 46 to 70

3730

32.5 - 35.0

33.7

Males aged 46 to 70 from GPs

2817

40.5 -42.5

41.5

Hospitalised Males aged 46 to 70

1943

31.7-35.1

33.4

Females aged > 70 from GPs

1486

37.6 - 39.9

38.8

Hospitalised Females aged > 70

2646

29.3 - 32.5

30.9

Males aged >70 from GPs

949

37.5 - 40.6

39.1

Hospitalised Males aged > 70

1202

28.7 - 33.2

31.0
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Female Albumin 95% CL Reference Intervals
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CUHQR AllGPs AllFGP AllHF 18-45GP 18-4511 46-70GP 4^70H > 70GP > 70H

n

Group
Male Albumin 95% CL Reference Intervals
48
47
46
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40
0£ 39
S
38
B 37
3
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< 35
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i
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Group
Blue - CUH Quoted Reference range
Green - GP Patients
Red - Hospitalised Patients

Figure 6. Graphical Representation of Albumin Reference Intervals
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ALKALINE PHOSPHATASE

Table 7. Number, Reference Intervals and Means for ALK PHOS

Number “n”
CUH Quoted Reference Range

Reference Interval
U/L
M:!5-20y; 50- 180
>20y; 40- 130
(25% range = 22.5)
F: >15y ; 35-110
(25% range = 18.8)

Mean
U/L
115
85
71.5

Olympus AU 5400 May ’05 Interval

22540

88.8- 1 13.3

101.8

Olympus AU 640 May ’05 Interval

1668

97.4 - 196.1

146.7

All from GPs

13433

84.8 - 93.3

89.0

All Females from GPs

7794

81.1-91.7

86.4

All Males from GPs

5443

83.2 - 101.8

92.5

All Hospitalised Females

9139

104.8 - 138.2

121.5

All Hospitalised Males

4516

102.3 - 144.9

123.6

Females aged 18 to 45 from GPs

2630

66.2 - 77.7

71.9

Hospitalised F'emales aged 18 to 45

2120

83.3 - 1 18.4

100.8

Males aged 18 to 45 from GPs

1512

73.2 - 93.8

83.5

I lospitalised Males aged 18 to 45

1060

78.7 - 123.1

100.9

Females aged 46 to 70 from GPs

3633

84.8 -93.3

89.0

Hospitalised Females aged 46 to 70

4029

102.3 - 154.3

128.3

Males aged 46 to 70 from GPs

2823

78.4 - 97.8

88.1

Hospitalised Males aged 46 to 70

2099

88.1 - 166.8

127.5

Females aged > 70 from GPs

1492

83.2- 114.5

98.9

Hospitalised Females aged > 70

2813

107.4 - 128.2

117.8

Males aged >70 from GPs

949

77.6 - 125.7

101.6

Hospitalised Males aged > 70

1260

101.2 - 143.3

122.3
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Female Alkaline Phosphatase (ALP) 95% CL Reference Interv als
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Figure 7. Graphical Representation of Aik Phos Reference Intervals
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ALANINE TRANSAMINASE (ALT)
Table 8. Number, Reference Intervals and Means for ALT

Number “n”

CliH Quoted Reference Range

Reference Interval
U/L
4.0 - 45
(25% range = 10)
26.7 - 35.6

Mean
U/L
24.5

Olympus AU 5400 May ’05 Interval

22538

Olympus AU 640 May ’05 Interval

1631

9.48 - 72.6

41.1

All from GPs

13434

24.43 - 32.8

28.6

All Females from GPs

7797

19.18-30.9

25.0

All Males from GPs

5443

29.1 -38.4

33.8

All Hospitalised Females

9130

27.3 - 46.4

36.9

All Hospitalised Males

4510

31.0-46.8

38.9

Females aged 18 to 45 from GPs

2490

1 1.2 -37.4

24.3

Hospitalised Females aged 18 to 45

2114

26.3 - 43.0

34.7

Males aged 18 to 45 from GPs

1512

30.1 -46.2

38.2

Hospitalised Males aged 18 to 45

1056

29.8 - 55.6

42.7

Females aged 46 to 70 from GPs

3635

19.4-34.4

26.9

Hospitalised Females aged 46 to 70

4028

23.8 - 57.0

34.7

Males aged 46 to 70 from GPs

2823

28.7-41.6

38.2

Hospitalised Males aged 46 to 70

2098

28.1 - 52.5

40.3

Females aged > 70 from GPs

1492

8.4-35.7

22.0

Hospitalised Females aged > 70

2812

23.0 -42.1

32.6

Males aged > 70 from GPs

949

16.7-32.4

24.5

Hospitalised Males aged > 70

1259

18.6-45.1

31.9

31.2
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Female Alanine Transaminase (ALT) 95% CL Reference Intervals
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Figure 8. Graphical Representation of ALT Reference Intervals
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AMYLASE

Table 9. Number, Reference Intervals and Means for AMYLASE

Number “n”

Reference Interval
(25% of range = 31)
U/L

CUH Quoted Reference Range

28-150

Mean
U/L
89

Olympus AU 5400 May ’05 Interval

162

10.8 - 134 (26th elim)

72.5

Olympus AU 640 May ’05 Interval

336

18.8- 118.7

68.7

All from GPs

57

24.9- U 1.4

68.1

All Females from GPs

25

26.2-109

67.6

All Males from GPs

34

18.2- 100.8

59.5

All Hospitalised Females

431

7.7 - 151.7

79.7

All Hospitalised Males

204

65.0

Females aged 18 to 45 from GPs

11

25.9- 104.1
(20+3 lelim)
24.2- 119.2

Hospitalised Females aged 18 to 45

168

19.8- 109.5

64.6

Males aged 18 to 45 from GPs

15

0(?-2.2)- 1 1 1.9

54.9

Hospitalised Males aged 18 to 45

72

0 (?-46.2) - 202.4

78.1

Females aged 46 to 70 from GPs

10

19.9- 112.9

66.4

Hospitalised Females aged 46 to 70

151

56.0

Males aged 46 to 70 from GPs

16

33.8 - 78.2 (20+31
elim)
22.1 - 101.4

Hospitalised Males aged 46 to 70

90

Females aged > 70 from GPs

71.2

61.8
59.9

2

23.1 -96.6(20+31
elim)
N/A only 2 (53, 108)

N/A

Hospitalised Females aged > 70

85

9.2- 112.1

60.6

Males aged > 70 from GPs

3

N/A only 2 (48, 57)

N/A

Hospitalised Males aged > 70

35

25.9 -90.5

58.2
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Figure 9. Graphical Representation of AMYLASE Reference Intervals
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CALCIUM
Table 10. Number, Reference Intervals and Means for CALCIUM
—

Number
“n”
CUH Quoted Reference Range

Reference Interval
mmol/L
2.10-2.62
(25% range = 0.13)
2.23-2.35

Mean
mmol/L
2.36

Olympus AU 5400 May ’05 Interval

22471

Olympus AU 640 May ’05 Interval

970

2.05 - 2.33

2.19

All from GPs

12985

2.28 - 2.39

2.34

All Females From GPs

7559

2.28-2.39

2.34

All Males from GPs

5237

2.28-2.39

2.34

All Hospitalised Females

8435

2.18-2.27

2.23

All Hospitalised Males

4184

2.17-2.26

2.22

Females aged 18 to 45 from GPs

2477

2.27-2.38

2.32

Hospitalised Females aged 18 to 45

1846

2.23 - 2.34

2.29

Males aged 1 8 to 45 from GPs

1433

2.30 - 2.43

2.37

1 lospitalised Males aged 18 to 45

922

2.22-2.36

2.29

Females aged 46 to 70 from GPs

3547

2.30-2.40

2.35

Hospitalised Females aged 46 to 70

3771

2.18-2.27

2.23

Males aged 46 to 70 from GPs

2715

2.27-2.39

2.33

1 lospitalised Males aged 46 to 70

1968

2.16-2.25

2.21

Females aged > 70 from GPs

1444

2.27-2.40

2.33

Hospitalised Females aged > 70

2680

2.14-2.23

2.18

Males aged >70 from GPs

935

2.24-2.35

2.29

I lospitalised Males aged > 70

1218

2.09-2.24

2.16

2.29
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Figure 10. Graphical Representation of CALCIUM Reference Intervals
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CHLORIDE
Table 11. Number, Reference Intervals and Means for CHLORIDE
Number “n”

CUH Quoted Reference Range

Reference Interval
mmol/L

Mean
mmol/L
101.0

Olympus AU 5400 May ’05 Interval

22960

95 - 107
(25% of range = 3)
101.4- 103.2

Olympus AU 640 May ’05 Interval

3364

100.6- 103.8

102.2

All from GPs

13436

101.7- 103.1

102.4

All Females from GPs

7790

101.8- 103.4

102.6

All Males from GPs

5450

101.2 - 103.0

102.1

All Hospitalised Females

10830

101.6- 103.5

102.5

All Hospitalised Males

5369

101.1 - 103.7

102.4

Females aged 18 to 45 from GPs

2488

102.1 - 104.3

103.2

Hospitalised Females aged 18 to 45

2534

101.9- 104.3

103.1

Males aged 18 to 45 from (jPs

1513

100.6- 103.1

101.9

Hospitalised Males aged 18 to 45

1262

101.5 - 103.8

102.6

Females aged 46 to 70 from GPs

3628

101.9- 104.3

102.9

Hospitalised Females aged 46 to 70

4648

101.3 - 103.7

102.5

Males aged 46 to 70 from GPs

2824

101.3 - 103.2

102.3

Hospitalised Males aged 46 to 70

2446

100.4 - 103.6

102.0

Females aged > 70 from GPs

1493

99.5 - 102.9

101.2

Hospitalised Females aged > 70

3313

101.1 - 103.2

102.1

Males aged >70 from GPs

954

100.3 - 103.2

102

Hospitalised Males aged > 70

1484

101.2 - 104.6

102.9

102.0
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Figure 11. Graphical Representation of CHLORIDE Referenee Intervals
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CHOLESTEROL

Table 12. Number, Reference Intervals and Means for CHOLESTEROL

Number
“n”

Reference Interval
mmol/L
3.5 - 5.0
(25% of range = 0.38)

Mean
mmol/L
4.25

Olympus AU 5400 May '05 Interval

23226

4.75 - 5.15

4.95

Olympus AU 640 May ’05 Interval

359

4.13 - 5.65

4.89

All from GPs

14051

5.15-5.34

5.25

All Females from GF’s

8118

5.23-5.43

5.33

All Males from GPs

5730

5.15 - 5.34

5.12

All Hospitalised Females

7948

4.31 - 4.65

4.48

All Hospitalised Males

3937

4.00-4.50

4.25

Females aged 1 8 to 45 from GPs

2532

4.85 - 5.27

5.06

1 lospitalised Females aged 1 8 to 45

1732

4.44 - 5.08

4.76

Males aged 18 to 45 from GPs

1568

5.02-5.49

5.26

Flospitalised Males aged 18 to 45

869

4.23 - 5.29

4.76

Females aged 46 to 70 from GPs

3848

5.43-5.72

5.57

Hospitalised Females aged 46 to 70

3581

4.38-4.83

4.61

Males aged 46 to 70 from GPs

3017

5.10-5.43

5.27

Hospitalised Males aged 46 to 70

1863

3.94-4.57

4.26

Females aged > 70 from GPs

1557

5.06-5.53

5,29

Hospitalised Females aged > 70

2521

3.80-4.39

4.10

Males aged > 70 from GPs

987

4.29 - 5.09

4.69

Hospitalised Males aged > 70

1 141

3.43-4.22

3.83

CUH Quoted Reference Range
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Figure 12. Graphical Representation of CHOLESTEROL Reference Intervals
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CREATININE

Table 13. Number, Reference Intervals and Means for CREATININE

Number
“n”

Reference Interval
^mol/L

Mean
jimol/L
90

Olympus AU 5400 Vlay ’05 Interval

22825

50 - 130
(25% of range = 20)
79.2 - 125.7

102.5

Olympus AU 640 May ’05 Interval

3183

94.2 - 167.2

130.7

All from GPs

13441

85.8-93

89.4

All Females from GPs

7793

79.5 - 85.6

82.6

All Males from GPs

5452

94.5 - 104.1

99.3

All Hospitalised Females

1 1300

84.5 - 168.4

126.5

All Hospitalised Males

5370

81.7 - 206.4

144

Females aged 1 8 to 45 from GPs

2489

72.8-81.6

77.2

1 lospitalised Females aged 18 to 45

2534

69.9 - 195.5

132.7

Males aged 18 to 45 from GPs

1512

83.5 - 109.9

96.7

I lospitalised Males aged 18 to 45

1262

51.2 - 236.6

143.9

Females aged 46 to 70 from GPs

3630

78.3 - 84.9

98.1

Hospitalised Females aged 46 to 70

4654

67.6 - 182.2

124.9

Males aged 46 to 70 from GPs

2827

94.8- 101.3

98.1

Hospitalised Males aged 46 to 70

2449

72.3-215.4

143.9

Females aged > 70 from GPs

1493

87.0 - 103.7

95.3

Hospitalised Females aged > 70

3315

104.2 - 166.0

135.1

Males aged > 70 from GPs

954

101.5- 121.9

11 1.7

Hospitalised Males aged > 70

1485

108.6- 200.0

154.3

CUH Quoted Reference Range
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Figure 13. Graphical Representation of CREATIIVINE Reference Intervals
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GAMMA GLUTAMYL TRANSFERASE (GGT)

Table 14. Number, Reference Intervals and Means for GGT

Number “n”

CUH Quoted Reference Range

Reference Interval
U/L

Mean
U/L

6.0 - 48

27

Olympus AU 5400 May ’05 Interval

1264

67.4- 171.6

119.5

Olympus AU 640 May ’05 Interval

103

0(-47.2)- 361.0

156.9

All from GPs

709

25.3 - 150.5

87.9

All Females from GPs

363

7.4- 126.1

66.7

All Males from GPs

331

0 (-15.1)- 237.5

111.2

All Hospitalised Females

561

42.6 - 303.6

173.1

All Hospitalised Males

281

0 (-29.2)-438.6

204.7

Females aged 1 8 to 45 from GPs

135

0 (-7.9)-87.8

40.0

Hospitalised Females aged 18 to 45

165

0 (-85.6)- 329.0

121.7

Males aged 18 to 45 from GPs

116

0 (-85.2)-276.6

95.7

Hospitalised Males aged 1 8 to 45

89

0 (-198.6)- 507.9

154.7

Females aged 46 to 70 from GPs

179

12.3 - 109.7

61.0

Hospitalised Females aged 46 to 70

278

14.9 - 387.4

201.1

Males aged 46 to 70 from GPs

181

0 (-56.3)-310.4

127.1

Hospitalised Males aged 46 to 70

136

11.3 - 384.7

198.0

Females aged > 70 from GPs

44

0 (-283.9)- 708.4

209.7

Hospitalised Females aged > 70

101

0 (-80.9) - 420.7

169.9

Males aged > 70 from GPs

30

0(-36.7)- 160.2

61.7

Hospitalised Males aged > 70

48

0 (-334.4)- 801.7

233.7
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Figure 14. Graphical Representation of GGT Reference Intervals
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HIGH DENSITY LIPOPROTEIN (HDL) CHOLESTEROL

Table 15. Number, Reference Intervals and Means for HDL

Number “n”
CUH Quoted Reference Range

Reference Interval
mmol/L
M: 1.0 - 1.7

Mean
mniol/L
135

25% of M range = 0.2

F: 0.9 - 2.2
25% of t- range = 0.3

1.55

Olympus AU 5400 May ’05
Interval
Olympus AU 640 May ’05 Interval

7163

1.35 - 1.47

1.41

74

0.96- 1.69

1.32

All from GPs

6272

1.39- 1.47

1.43

All Females from GPs

3448

1.48- 1.60

1.54

All Males from GPs

2737

1.24- 1.34

1.29

All Hospitalised Females

701

1.13- 1.37

1.25

All flospitalised Males

377

1.00- 1.29

1.15

Females aged 18 to 45 from GPs

686

1.36- 1.63

1.50

Flospitalised Females aged 1 8 to
45
Males aged 18 to 45 from GPs

139

0.91 - 1.61

1.26

624

1.19- 1.39

1.29

Hospitalised Males aged 18 to 45

75

0.78- 1.51

1.14

Females aged 46 to 70 from GPs

2070

1.50- 1.63

1.56

Flospitalised Females aged 46 to
70
Males aged 46 to 70 from GPs

372

1.03 - 1.44

1.23

1653

1.24- 1.37

1.30

Hospitalised Males aged 46 to 70

212

0.99- 1.24

1.12

Females aged > 70 from GPs

675

1.38- 1.70

1.54

Hospitalised Females aged > 70

181

1.03 - 1.42

1.23

Males aged > 70 from GPs

445

1.05 - 1.49

1.27

87

0.72- 1.67

1.19

Hospitalised Males aged > 70
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Figure 15. Graphical Representation of HDL Reference Intervals
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IRON

Table 16. Number, Reference Intervals and Means for IRON

Number “n”

CL!H Quoted Reference Range

Reference Interval
fimol/L

Mean
jumol/L

9.0 - 28

18.5

(25% range = 4.8)

Olympus AU 5400 May ’05 Interval

576

10.8-21.8

16.3

Olympus AU 640 May ’05 Interval

40

0(-l,2)-25.6

12.2

All from GPs

167

14.7-29.6

22.1

All Females from GPs

75

7.7-31.4

19.5

Ail Males from GPs

86

14.0-37.0

25.5

All Hospitalised Females

272

6.4 - 19.7

13.0

All Hospitalised Males

155

5.4-22.6

14.0

Females aged 18 to 45 from GPs

30

6.3 - 32.5

19.4

Hospitalised Females aged 18 to 45

70

1.7-24.6

13.1

Males aged 1 8 to 45 from GPs

34

9.5-38.7

24.1

Hospitalised Males aged l8to45

40

0.3 - 25.6

13.0

Females aged 46 to 70 from GPs

35

5.3-37.5

21.4

Hospitalised Females aged 47 to 70

133

3.7-27

15.4

Males aged 46 to 70 from GPs

45

13.9-37.7

24.1

Hospitalised Males aged 46 to 70

83

1.6-29.3

15.4

Females aged > 70 from GPs

10

0 (-0.04)- 30.5

15.2

Hospitalised Females aged > 70

63

0.9- 15.5

8.2

Males aged > 70 from GPs

5

3.7-41.6

22.6

Hospitalised Males aged > 70

31

0.2- 17.5

8.9
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Figure 16. Graphical Representation of IRON Reference Intervals
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LOW DENSITY LIPOPROTEIN (LDL)
Table 17. Number, Reference Intervals and Means for LDL

Number “n”

CUH Quoted Reference Range

Reference Intei*val
mmol/L

Mean
mmol/L

2.1-3.0

2.55

(25% range = 0.23)

Olympus AU 5400 May ’05 Interval

N/A

N/A

N/A

Olympus AU 640 May ’05 Interval

N/A

N/A

N/A

All from GPs

6146

3.11 -3.34

3.23

All Females from GPs

3407

3.14-3.45

3.30

All Males from GPs

2654

2.95-3.30

3.12

All Hospitalised Females

680

2.46-3.28

2.87

All Hospitalised Males

360

2.10-3.55

2.82

Females aged 18 to 45 from GPs

677

2.83-3.51

3.17

I lospitalised Females aged 18 to 45

134

2.22-4.17

3.19

Males aged 18 to 45 from (jPs

592

2.84 - 3.80

3.32

Hospitalised Males aged 18 to 45

70

1.96-4.32

3.14

Females aged 46 to 70 from GPs

2044

3.19-3.56

3.38

Hospitalised Females aged 46 to 70

356

2.29-3.39

2.84

Males aged 46 to 70 from GPs

1604

2.94-3.39

3.16

Hospitalised Males aged 46 to 70

200

2.09-3.43

3.14

Females aged > 70 from GPs

669

2.80-3.58

3.19

Hospitalised Females aged > 70

181

2.02-3.32

2.67

Males aged > 70 from GPs

443

2.30-3.28

2.79
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Figure 17. Graphical Representation of LDL Reference Intervals
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POTASSIUM

Table 18. Number, Reference Intervals and Means for POTASSIUM

Number
“n”

Olympus AIJ 5400 May ’05 Interval

22943

Reference Interval
mmol/L
3.5 - 5.0
(25% range = 0.38)
mmol/L
4.47 - 5.04

Olympus AU 640 May ’05 Interval

3346

4.09-5.19

4.64

All from GPs

12362

4.53 - 4.98

4.76

All Females from GPs

7217

4.51 -5.0

4.73

All Males from GPs

4964

4.56-5.03

4.80

All Hospitalised Females

10597

4.23-4.41

4.33

All Hospitalised Males

5080

4.29-4.45

4.37

Females aged 18 to 45 from GPs

2291

4.37 - 5.05

4.71

Hospitalised Females aged 18 to 45

2414

4.16-4.52

4.34

Males aged 18 to 45 from GPs

1362

4.56-5.08

4.82

Hospitalised Males aged 1 8 to 45

1200

4.19-4.53

4.35

Females aged 46 to 70 from GPs

2581

4.51 -4.97

4.74

Hospitalised Females aged 46 to 70

4348

4.24-4.41

4.32

Males aged 46 to 70 from GPs

2581

4.51 -5.08

4.79

Hospitalised Males aged 46 to 70

2321

4.28-4.45

4.36

Females aged > 70 from GPs

1375

4.54-4.98

4.76

Hospitalised Females aged > 70

3119

4.24 - 4.43

4.34

Males aged > 70 from GPs

881

4.59-5.03

4.81

Hospitalised Males aged > 70

1402

4.26-4.55

4.41

CUH Quoted Reference Range

Mean
mmol/L
4.25
mmol/L
4.76
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Figure 18. Graphical Representation of POTASSIUM Reference Intervals

88

SODIUM

Table 19. Number, Referenee Intervals and Means for SODIUM
Number “n”

CliH Quoted Reference Range

Reference
Interval
mmol/L

Mean
mmol/L

132 - 144
(25% of range = 3)

138

Olympus AU 5400 May ’05 Interval

22943

137.8 - 140.1

138.9

Olympus AU 640 May ’05 Interval

3357

135.6 - 138.7

137.1

All from GPs

13433

138.7 - 140.3

139.5

All Females from GPs

7788

138.6- 140.2

139.4

All Males from GPs

5612

138.6 - 140.4

139.5

All Hospitalised Females

10828

137.3 - 138.5

137.9

All Hospitalised Males

5368

137.1 - 138.7

137.9

2486

138.2 - 140.2

139.2

Hospitalised Females aged 18 to 45

2532

137.4 - 139.1

138.2

Males aged 18 to 45 from GPs

1512

138.7 - 140.8

139.8

Hospitalised Males aged 18 to 45

1262

137.3 - 139.5

138.4

Females aged 46 to 70 from GPs

3628

139.0- 140.9

139.9

Hospitalised Females aged 46 to 70

4649

137.5 - 138.7

138.1

Males aged 46 to 70 from GPs

2825

138.7 - 140.6

139.7

Hospitalised Males aged 46 to 70

2446

136.7 - 138.4

137.6

Females aged > 70 from GPs

1493

137.4 - 140.1

138.7

Hospitalised Females aged > 70

3312

136.7 - 138.4

137.5

Males aged > 70 from GPs

953

137.5 - 140.2

138.8

Hospitalised Males aged > 70

1483

136.6 - 139.4

138.0

Females aged 18 to 45 from CJPs
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Figure 19. Graphical Representation of SODIUM Reference Intervals
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TOTAL BILIRUBIN
Table 20. Number, Reference Intervals and Means for TOTAL BILIRUBIN
Number “n”

CUH Quoted Reference Range

Reference Interval
^mol/L

Mean
^mol/L

2.0 - 20

11.0

(25% of range = 4.5)

Olympus AIJ 5400 May ’05 Interval

22533

9.4- 12.5

11.0

Olympus AU 640 May ’05 Interval

1729

13.2-39.2

26.1

All from GPs

13434

9.7- 11.0

10.3

All Females from GPs

7795

8.7-10.1

9.4

All Males from GPs

5443

10.7- 12.5

1 1.6

All Hospitalised Females

9134

10.1 - 15.8

12.9

All Hospitalised Males

4511

1 1.2- 19.6

15.4

Females aged 18 to 45 from GPs

2490

8.2- 10.2

9.2

Hospitalised Females aged 18 to 45

2034

8.8- 12.0

10.4

Males aged 1 8 to 45 from CjPs

1512

10.3 - 13.2

11.7

Hospitalised Males aged 18 to 45

1056

8.4- 15.5

12.0

Females aged 46 to 70 from GPs

2823

8.6- 10.6

9.6

Hospitalised Females aged 46 to 70

4025

10.0- 18.0

14.0

Males aged 46 to 70 from GPs

2823

10.2- 13.4

1 1.8

Hospitalised Males aged 46 to 70

2096

11.4-24.3

17.9

Females aged > 70 from GPs

1492

7.5- I 1.0

9.3

2813

8.2- 18.1

13.2

Males aged >70 from GPs

949

9.1 - 13.7

11.4

Hospitalised Males aged > 70

1261

4.9-22.9

13.9

Hospitalised Females aged > 70
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Figure 20. Graphical Representation of TOT. BILIRUBIN Reference Intervals
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TOTAL PROTEIN

Table 21. Number, Reference Intervals and Means for TOTAL PROTEIN
Number
“n”

CUH Quoted Reference Range

Reference
Interval
g/L
62-82
= 5)

Mean
g/L
72

(25% range

Olympus AU 5400 May ’05 Interval

22762

66.0-71.3

68.6

Olympus AU 640 May ’05 Interval

1681

63.1-68.8

65.9

All from GPs

13433

70.2 - 72.3

71.2

All Females from GPs

7794

69.8- 72.0

70.9

All Males from GPs

5443

70.6 - 72.8

71.7

All Hospitalised Females

9131

63.8 - 66.8

65.3

All Hospitalised Vlales

4511

63.7 - 66.8

65.2

Females aged 18 to 45 from GPs

2490

70.3 - 73.0

71.7

Hospitalised Females aged 18 to 45

2118

66.2 - 70.5

68.3

Males aged 18 to 45 from GPs

1512

71.4-74.9

73.2

1 lospitalised Males aged 18 to 45

1058

65.3 - 70.6

67.9

Females aged 46 to 70 from GPs

3632

69.8 - 71.9

70.9

1 lospitalised Females aged 46 to 70

4025

63.4 - 67.2

65.3

Vlales aged 46 to 70 from GPs

2823

70.3 - 72.7

71.5

Hospitalised Males aged 46 to 70

2127

63.1 - 66.9

65.0

Females aged > 70 from GPs

1492

67.9-71.2

69.5

Hospitalised Females aged > 70

2812

61.2-64.4

62.8

Vlales aged > 70 from GPs

949

68.7-71.3

70.0

Hospitalised Vlales aged > 70

1228

60.8 - 65.4

63.1
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Figure 21. Graphical Representation of TOTAL PROTEIN Reference Intervals
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TRIGLYCERIDES
Table 22. Number, Reference Intervals and Means for Triglycerides
Number “n”

CUH Quoted Reference Range

Reference Interval
mmol/L

Mean
mmol/L

0.3 - 1.7
(25®/o of range =0.35)

1.0

Olympus AU 5400 May ’05 Interval

7972

1.52 - 1.79

1.66

Olympus AU 640 May ’05 Interval

107

0.16-3.66

1.91

All from GPs

6986

1.49- 1.83

1.66

Ail Females from GF^s

3821

1.34- 1.63

1.48

All Males from GPs

3068

1.58-2.16

1.87

All Hospitalised Females

800

1.33-2.33

1.83

All Hospitalised Males

430

1.07-3.04

2.05

Females aged 1 8 to 45 from GPs

774

1.10-1.58

1.34

Hospitalised Females aged 18 to 45

163

0.80-3.03

1.92

Males aged 18 to 45 from GI’s

713

1.53 - 2.66

2.1

Hospitalised Males aged 18 to 45

89

0.54 - 3.90

2.22

Females aged 46 to 70 from GPs

2271

1.33 - 1.72

1.53

Hospitalised Females aged 46 to 70

416

1.08-3.11

2.1

Males aged 46 to 70 from GPs

1849

1.52-2.29

1.9

Hospitalised Males aged 46 to 70

237

1.06-3.44

2.25

Females aged > 70 from GPs

758

1.21-1.83

1.52

Hospitalised Females aged > 70

202

0.96- 1.94

1.45

Males aged > 70 from GPs

486

1.06- 1.80

1.43

Hospitalised Males aged > 70
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0.61 -2.13

1.37
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Figure 22. Graphical Representation of TRIGLYCERIDES Reference Intervals
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URATE
Table 23. Number, Reference Intervals and Means for Urate
Number
“n”

Reference Interval
p.mol/L
M: 212-482

Mean
|Limol/L
347

(25% range = 68)

CUH Quoted Reference Range

F: 135-360

248

(25% range = 56)

Olympus AU 5400 May ’05 Interval

3107

307.7 - 363.3

335.5

Olympus AU 640 May ’05 Interval

181

266.2 -406.5

336.4

All from GPs

495

316.0-414.8

365.4

All Females from GPs

214

257.7 -373.3

315.5

All Males from GPs

270

335.8 - 471.5

403.6

All Hospitalised Females

2516

295.9 - 362.8

329.4

All Hospitalised Males

1278

335.8 - 471.5

351,1

Females aged 18 to 45 from (iPs

56

175.2 - 323.3

249.2

Hospitalised Females aged 18 to 45

613

259.0 - 363.0

311.0

Males aged 18 to 45 from GPs

60

236.6 - 532.7

384.7

Hospitalised Males aged 18 to 45

312

256.3 -427.1

341.7

Females aged 46 to 70 from GPs

111

223.6 -436.3

329.9

Hospitalised Females aged 46 to 70

1120

273.5 - 362.7

318.1

Males aged 46 to 70 from GPs

140

326.5 -493.0

409.8

Hospitalised Males aged 46 to 70

619

277.0 - 401,1

339.1

250.1 - 511.3

380.7

Females aged >70 from GPs

47

Hospitalised Females aged > 70

631

302.1 -418.8

360.5

Males aged >70 from GPs

65

261.9 - 542.4

402.1

Hospitalised Males aged > 70

322

300.5 -460.2

380.3
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Figure 23. Graphical Representation of URATE Reference Intervals
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UREA
Table 24. Number, Reference Intervals and Means for Urea
Number “n”
CUH Quoted Reference Range

Reference Interval
mmol/L
2.5 - 7.0
(25% range =1.13)
5.94 - 7.27

Mean
mmol/L
4.75

Olympus AU 5400 May ’05 Interval

22828

Olympus AU 640 May ’05 Interval

3199

5.92-9.65

7.78

All from GPs

13440

5.64 - 6.15

5.89

All Females from GPs

7792

5.29-5.89

5.59

All Males from GPs

5452

6.03 - 6.65

6.34

All Hospitalised Females

10834

6.65 -9.03

7.84

All Hospitalised Males

5370

6.68 - 10.15

8.41

Females aged 18 to 45 from GPs

2488

4.09-4.79

4.44

I lospitalised Females aged 1 8 to 45

2535

4.88 - 7.47

6.17

Males aged 18 to 45 from GPs

1512

5.26 - 5.98

5.62

Hospitalised Males aged 18 to 45

1262

4.58 - 8.76

6.67

Females aged 46 to 70 from GPs

3630

5.37-6.04

5.71

Hospitalised Females aged 46 to 70

4650

5.88 - 8.98

7.43

Males aged 46 to 70 from GPs

2827

6.00 - 6.55

6.26

Hospitalised Males aged 46 to 70

2447

5.87 - 10.45

8.18

Females aged > 70 from GPs

1493

Hospitalised Females aged > 70

3314

8.32 - 11.48

9.9

Males aged > 70 from GPs

954

6.80-9.06

7.93

Hospitalised Males aged > 70

1484

8.55 - 13.13

10.84

6.26 - 8.62

6.61

7.44
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Figure 24. Graphical Representation of UREA Referenee Intervals
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5.3: Investigation of Analyte Performance in Relation to Reference
Intervals
As discussed, the analytical performance of an assay matters a great deal when
reporting reference intervals. Cut-off points at which the clinician makes important
decisions may be affected positively or negatively by the method employed in the
assay. It is therefore very important to determine the quality of the results being
generated. In the third part of this project, details of the performance of the 19
analytes are presented below. The analytical coefficients of variations (CVa) were
ealculated by averaging the monthly CVs of the Internal Quality Controls (IQC),
Beckman Triad 2 and Triad 3. The Bias figure (Ba) for each assay was taken from
ILxternal Quality Assessment (E^QA) the UK NEQAS for clinical chemistry report distribution 746, dated 16‘*’ May 2005. The calculations used for total error allowable
based on biological variation are given. F.xamples of all three levels are included,
desirable, minimum, and optimum. Also presented are the recommended desirable
quality specifications for total error allowable based on biological variation, the CflA
'88 Total I'lTor Allowable, and the Index of Individuality.'^'^

Assay Performance of Individual Analytes
The tables of analyte performance are presented in alphabetical order.

01

Albumin
Table 25. Q.S. Details for Albumin, with CUH performance during the study in red
Desirable Quality Specification for Albumin Precision CVa

1.6%

CUH May 2005 Precision for Albumin - CVa

0.9 %

Desirable Quality Specification for Albumin Bias Ba

1.3%

CUH May 2005 Bias for Albumin Assay
Desirable Quality Specification for Precision TEa

-0.15 %
3.9%

Total Error based on biological variation for Albumin Assay
CVa (0.9) < 0.50CV, (0.5 x 3.1 = 1.55) and Ba(-0.15 )<
0.250(CVr+ CVg-)' - i.e. <0.25(3.12+4.22)'''’ = t.28

Desirable QS
Achieved*

Within-subject Biological Variation CV|

3.1 %

Between-subject Biological Variation CVq

4.2 %

CTIA ,88 Total Error Allowed, Albumin target value

± 10%

Index of Individuality for Albumin

0.74

* Desirable Quality Specification for total error based on biological variation
when CVa < O.SOCV, and Ba < 0.250(CV|^ +
then
FEa < 1.65(0.50CV|) + 0.250(CV,^ + CVc’)''-

Alkaline Phosphatase (ALP)
Fable 26. Q.S. Details for AL.P, with CUH performance of May 2005, in red
Desirable Quality Specification for ATP Precision CVa

3.2 %

CUH May 2005 Precision for ALP Assay CVa

1.55%

Desirable Quality Specification for ALP Bias Ba

6.4 %

CUH May 2005 Bias for ALP Assay Ba
Desirable Quality Specification for Precision TEg

+12.43%
11.7%

Total Error based on biological variation allowed for ALT Assay
CVa (1.55) < 0.75CV, (0.75 x 6.4) = 4.8 and Ba( +12.43) NOT<
0.375(CVr+ CVg-)''- i.e. <0.375{6.4-+24.8^)'''’ =9.6

Minimum QS
NOT Achieved^

Within-subject Biological Variation CVi

6.4 %

Between-subject Biological Variation CVg

24.8 %

CLIA ,88 Total EiTor Allowed, ALP target value

± 30%

Index of Individuality for ALP

0.84

^'ote The CVa was not less than 0.5 CV i therefore the formula for minimum QS for
total allowable error was used CVa < 0.75CV i with Ba < 0.375 (CVj^ + CVg^)'^^
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Alanine Aminotransferase (ALT)
Table 27. Q.S. Details for Al.T, with CUH performance of May 2005, in red
Desirable Quality Specification for ALT Precision CVa

12.2%

CUH May 2005 Precision for ALT Assay

0.85%

Desirable Quality Specification for ALT Bias Ba

2.0%

CUH May 2005 Bias for ALT Assay

-2.73%

Desirable Quality Specification for Precision TEg

32.1%

Total Error based on biological variation allowed for ALT assay

Optimum
CVa (0.85) < 0.25CVi (0.25 x 24.3 = 6.1) and Ba(-2.73 )< QS
Achieved’*^
O.I25(CVi^ + CVo^)‘'^ i.e. <0.125(24.3^+41.6^’''“ =6.0
Within-subject Biological Variation CV|

24.3%

Between-subject Biological Variation CVq

41.6%

CLIA ,88 Total Error Allowed, ALT target value

± 20%

Index of Individuality for AIT

0.58

/Vb Vw. V /\ Wcli

V.

G )‘

Optimum QS was used.

Amylase
Table 28. Q.S. Details for Amylase, with CUH performance of May 2005, in red
Desirable Quality Specification for Amylase Precision CVa

4.8%

CUH May 2005 Precision for Amylase Assay

1.21%

Desirable Quality Specification for Amylase Bias Ba

7.8%

CUH May 2005 Bias for Amylase Assay
Desirable Quality Specification for Precision TEg
Total Error based on biological variation allowed for Amylase assay
CVa (1.21) < 0.250CV| (0.25 x 9.5 = 2.4) and Ba(-1.65 )<
0.125(CV|- + CVg^)''- i.e. <0.125(9.5^+29.8^’''“ =3.9

-1.65%
15.7%
Optimum
QS
Achieved

Within-subject Biological Variation CV|

9.5%

Between-subject Biological Variation CVg

29.8%

CLIA ,88 Total Error Allowed, Amylase target value

± 30%

Index of Individuality for Amylase

0.32
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Calcium
Table 29. Q.S. Details for Calcium, with CUH performance of May 2005, in red
Desirable Quality Specification for Calcium Precision CVa

1.0%

CUH May 2005 Precision for Calcium Assay

1.16%

Desirable Quality Specification for Calcium Bias Ba

0.80%

CUH May 2005 Bias for Calcium Assay

+0.34%

Desirable Quality Specification for Precision TEa

2.4%

Total Error based on biological variation allowed for Calcium Assay

Minimum
CVa (1.16) < 0.75CV, (0.75 x 1.9) = 1.43 and Ba( +0.34 ) < QS
Achieved^
0.375(CV|- + CVtr)''^ i.e. <0.375(1.9^+2.8-)'''‘ =1.70
Within-subject Biological Variation CV|

1.9%

Between-subject Biological Variation CVg

2.8%

CITA ,88 Total Error Allowed, Calcium target value

± 0.5mmol/I.

Index of Individuality for Calcium

0.68

Cholesterol
Table 30. Q.S. Details for Cholesterol, with CUH performance of May 2005, in red
Desirable Quality Specification for Cholesterol Precision CVa

3.0%

CUH May 2005 Precision for Cholesterol Assay

0.68%

Desirable Quality Specification for Cholesterol Bias Ba

4.1%

CUH May 2005 Bias for Cholesterol Assay

+1.98%

Desirable Quality Specification for Precision TEa

9.0%

Total Error based on biological variation allowed for Cholesterol
assay
CVa (0.68) < 0.50CV| (0.5 x 6.0) = 3.0 and Ba(+1.98 ) <
0.250(CVf + CVg’)''^ i.e. <0.25(6.0^+15.2’= 4.08

Desirable
Achieved

Within-subject Biological Variation CV|

6.0%

Between-subject Biological Variation CV^

15.2%

CLIA ,88 Total Error Allowed, Cholesterol target value

± 10%

Index of Individuality for Cholesterol

0.40

QS
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Chloride
Table 31. Q.S. Details for Chloride, with CUH performance of May 2005, in red
Desirable Quality Specification for Chloride Precision CVa

0.6%

CUH May 2005 Precision for Chloride Assay

0.37%

Desirable Quality Specification for Chloride Bias Ba

0.5%

CUH May 2005 Bias for Chloride Assay

-0.60%

Desirable Quality Specification for Precision TEg

1.5%

Total Error based on biological variation allowed for Chloride assay

Minimum

CVa (0.37) < 0.75CV| (0.75 x 1.2) = 0.9 and Ba(>0.60 ) <
0.375(CV|^+ CVo-)''^ i.e. <0.375(1.2^+1.5^)'^’ =0.72

QS

Within-subject Biological Variation CVi

1.2%

Between-subject Biological Variation CVg

1.5%

CTIA ,88 Total Error Allowed, Chloride target value

± 5%

Index of Individuality for Chloride

0.80

Achieved

Creatinine
Table 32. Q.S. Details for Creatinine, with CUH performance of May 2005, in red
Desirable Quality Specification for Creatinine Precision CVa

2.2%

CUH May 2005 Precision for Creatinine Assay

1.71%

Desirable Quality Specification for Creatinine Bias Ba

3.4%)

CUH May 2005 Bias for Creatinine Assay

-0.07%)

Desirable Quality Specification for Precision TEg

6.9%

Total Error based on biological variation allowed for Creatinine
assay

Desirable
CVa (1.71) < 0.50CV, (0.5 x 4.3) = 2.15 and Ba(-0.07 ) < Achieved
0.250(CV|^+ CVg^)''^ i.e. <0.25(4.3^+12.9^)'''’ =3.40
Within-subject Biological Variation CVj

4.3%

Between-subject Biological Variation CVq

12.9%)

CLIA ,88 Total Error Allowed, Creatinine target value

± 15%

Index of Individuality for Creatinine

0.33

QS
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Gamma Glutamyl Transferase
Table 33. Q.S. Details for GOT, with CUH performance of May 2005, in red
Desirable Quality Specification for GOT Precision CV^

6.9%

CUH May 2005 Precision for GGT Assay

1.23%

Desirable Quality Specification for GGT Bias Ba

10.8%

CUH May 2005 Bias for GGT Assay

+6.37%

Desirable Quality Specification for Precision TEa

22.2%

Total Error based on biological variation allowed for GGT assay

Optimum

CVa (1.23) < O.25OCV1 (0.25 X 13.8) - 3.45 and Ba(-0.07 ) < QS
0.125(CV,^ + CVr,^)''^ i.e. <0,125(13.8^41.0^
=5.41
Achieved
Within-subject Biological Variation CVi

13.8%

Between-subject Biological Variation CVg

41.0%

CLIA ,88 Total Error Allowed, GGT target value

N/A

Index of Individuality for GGT

0.34

High Density Lipoprotein Cholesterol
fable 34. Q.S. Details for HDL, with CUH performance of May 2005, in red
Desirable Quality Specification for HDL Precision CVa

3.6%

CUH May 2005 Precision for HDL Assay

0.87%

Desirable Quality Specification for HDL Bias Ba

5.2%

CUH May 2005 Bias for HDL Assay

N/A

Desirable Quality Specification for Precision TEa

11.1%

Within-subject Biological Variation CV[

7.1%

Between-subject Biological Variation CVq

19.7%

Index of Individuality for HDL

0.36
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Iron
Table 35. Q.S. Details for Iron, with CUH performance of May 2005, in red
Desirable Quality Specification for Iron Precision CVa

13.3%

CUH May 2005 Precision for Iron Assay

N/A

Desirable Quality Specification for Iron Bias Ba

8.8%

CUH May 2005 Bias for Iron Assay

+1.35%

Desirable Quality Specification for Precision TEa

30.7%

Within-subject Biological Variation CVi

26.5%

Between-subject Biological Variation CVg

23.2%

CLIA ,88 Total Error Allowed, Iron target value

± 20%

Index of Individuality for Iron

1.14

Potassium
Table 36. Q.S. Details for Potassium, with CUH perfonnance of May 2005, in red
Desirable Quality Specification for Potassium Precision CVa

2.4%

CUH May 2005 Precision for Potassium Assay

0.7%

Desirable Quality Specification for Potassium Bias Ba

3.2%

CUH May 2005 Bias for Potassium Assay

+0.83%
5.8%

Desirable Quality Specification for Potassium Precision TEa
Total Error based on biological variation allowed for Potassium
assay
CVa (0.7) < 0.25 CV, (0.25 x 4.8) = 1.2 and Ba(+0.83 ) <
0.125(CV|^ + CVg^)''^ i.e. <0.125(4.8^+5.6^ )'•'■ =0.92

Optimum QS
Achieved

Within-subject Biological Variation CVi

4.8%

Between-subject Biological Variation CVg

5.6%

CLIA ,88 Total Error Allowed, Potassium target value
Index of Individuality for Potassium

±

0.5mmoI/L
1.02
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Sodium
Table 37. Q.S. Details for Sodium, with CUH performanee of May 2005, in red
Desirable Quality Specification for Sodium Precision CVa

0.4%

CUH May 2005 Precision for Sodium Assay

0.33%

Desirable Quality Specification for Sodium Bias Ba

0.3%

CUH May 2005 Bias for Sodium Assay

-0.63%

Desirable Quality Specification for Potassium Precision TEg

0.9%

Total Error based on biological variation allowed for Sodium Assay
CVa (0.33) < 0,75 CV, (0.75 x 0.7) = 0.53 and Ba(-0.63 ) NOT< Minimum
0.375(CV|^ + CVo^)‘'^ i.e. <0.375(0.7+1.0^ )'■'■ =0.46
QS
NOT
achieved
Within-subject Biological Variation CVi

0.7%

Between-subject Biological Variation CV^

1.0%

CLIA ,88 Total Error Allowed, Sodium target value

±

Index of Individuality for Sodium

0.7

4 mmoI/L

Total Bilirubin
fable 38. Q.S. Details for fotal Bilirubin, with CUH performanee of May 2005, in
red
Desirable Quality Specification for Total Bilirubin Precision CVa

12.8%

CUH May 2005 Precision for Total Bilirubin Assay

0.67%

Desirable Quality Specification for Total Bilirubin Bias Ba

10.0%

CUH May 2005 Bias for Total Bilirubin Assay
Desirable Quality Specification for Total Bilirubin Precision TEg
Total Error based on biological variation allowed for Total
Bilirubin assay
CVa (0.67) < 0.25 CV, (0.25 x 25.6) = 6.4 and a(+0.41 ) <
0.I25(CVi^ + CVg^)‘'^ i.e. <0.125(25.6^30.5^)’'' =4.98

+0.41%
31.1%
Optimum
QS
Achieved

Within-subject Biological Variation CV,

25.6%

Between-subject Biological Variation CVq

30.5%

CLIA ,88 Total Error Allowed, Total Bilirubin target value

± 20%

Index of Individuality for Total Bilirubin

0.84
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Total Protein
Table 39. Q.S. Details for Total Protein, with CUH performance of May 2005, in red
Desirable Quality Specification for Total Protein Precision CVa

1.4%

CUH May 2005 Precision for Total Protein Assay

1.56%

Desirable Quality Specification for Total Protein Bias Ba

1.2%

CUH May 2005 Bias for Total Protein Assay

-1.50%

Desirable Quality Specification for Total Protein Precision TEa

3.4%

Total Error based on biological variation allowed for Protein
assay
CVa (1.56) < 0.75 CV, (0.75 x 2.7) = 2.03 and Ba(-1.50 ) <
0.375(CV|^ + CVg^)''^ i.e. <0,375(2.7^+4.0^ )= 1.80

Minimum
QS
Achieved

Within-subject Biological Variation CVi

2.7%

Between-subject Biological Variation CVq

4.0%

CLIA ,88 Total Error Allowed, fotal Protein target value

± 10%

Index of Individuality for Total Protein

0.68

Triglycerides
Table 40. Q.S. Details for Triglycerides, with CUH performance of May 2005, in red
Desirable Quality Specification for Triglycerides Precision CVa

10.5%

CUH May 2005 Precision for Triglycerides Assay

0.72%

Desirable Quality Specification for Triglycerides Bias Ba

10.7%

CUH May 2005 Bias for Triglycerides Assay

+2.28%

Desirable Quality Specification for Triglycerides Precision TEa

27.9%

Total Error based on biological variation allowed for Triglyceride
assay

Optimum
QS

CVa (0.72) < 0.25 CV, (0.25 x 21.0) = 5.25 and Ba(+2.28 ) <
0.125(CV|^ f CVg^)''^ i.e. <0.125(21.0^+37.2^)’' = =5.34

Achieved

Within-subject Biological Variation CVi

21.0%

Between-subject Biological Variation CVq

37.2%

CLIA ,88 Total Error Allowed, Triglycerides target value

± 25%

Index of Individuality for Triglycerides

0.57
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Urate
Table 41. Q.S. Details for Urate, with CUH performance of May 2005, in red
Desirable Quality Specification for Urate Precision CVa

4.3%

CUH May 2005 Precision for Urate Assay

0.99%

Desirable Quality Specification for Urate Bias Ba

4.8%

CUH May 2005 Bias for Urate Assay
Desirable Quality Specification for Urate Precision TEa
Total Error based on biological variation allowed for Urate assay
CVa (0.99) < 0.25 CV, (0.25 x 8.6) = 2.2 and Ba(-2.4 ) <
0.125(CVi^ + CVg^)''^ i.e. <0.125(8.6^+17.2^)'''' =2.4

-2.42%
11.9%

Optimum
QS
Achieved

Within-subject Biological Variation CVi

8.6%

Between-subject Biological Variation CVg

17.2%

CLIA ,88 Total Error Allowed, Urate target value

± 17%

Index of Individuality for Urate

0.50

Urea
Table 42. Q.S. Details for Urea, with CUH performance of May 2005, in red
Desirable Quality Specification for Urea Precision CVa

6.2%

CUH May 2005 Precision for Urea Assay

1.69%

Desirable Quality Specification for Urea Bias Ba

5.5%

CUH May 2005 Bias for Urea Assay
Desirable Quality Specification for Urea Precision TEa

-5.35%
15.7%

Total Error based on biological variation allowed for Urea Assay

CVa (1.69) < 0.50 CV,

(0.50 x 12.3) = 6.2 and Ba(-5.35 ) <
0.250(CV|H CVo^)''^ i.e. <0.25(12.3^+18.3^)'''' =5.51

Desirable QS
Achieved

Within-subject Biological Variation CVj

12.3%

Between-subject Biological Variation CVq

18.3%

CLIA ,88 Total Error Allowed, Urea target value

±9%

Index of Individuality for Urea

0.67

10

6.0 Discussion
The aim of the clinical biochemistry laboratory is to aid clinicians in the management
of their patients. Why are reference ranges so important? All laboratory professionals
are aware that they are only a guide to the interpretation of laboratory tests since they
are so profoundly influenced by physiology, pathology and analytical factors. Yet,
despite this, reference ranges are given an unwarranted level of absolute truth by our
clinical colleagues. Is it merely a matter of education for clinicians? In the current
climate of evidence-based medicine, reference ranges might be the laboratory
expression of evidence. Laboratories are responsible for the tests they choose to
provide and should therefore be accountable for providing appropriate guidance on
the interpretation of these tests. Some guidance will be mandated e.g. glucose
concentrations that define diabetes or cholesterol concentrations that are used to guide
medication. Interpretation of other analytes is more problematic due to a lack of
generally accepted evidence and because local variations in population mix affect test
results, fhe IFCC series of papers on the development of reference ranges entail
studies of a magnitude that are outside the range for a routine clinical laboratory and
require enormous resources.
The best reference value with which to compare a patient’s result is an earlier result
on the same patient for that analyte. Horn and Pesce have proposed that all of the
individual’s data be traceable to national primary standards, national reference
methods and national definitive methods.Therefore these measurements will have a
known relationship to all data obtained over the succeeding 10, 20, or 30 years. They
have termed this the Medical Heritage Concept. Each individual would have his/her
own reference interval based on his history as well as that of his cohorts. This
practice would require access to longitudinal cohort data as well as to analytical
results standardised over time.
With three exceptions (glucose, cholesterol and HbAlc), there are no guidelines that
manufacturers meet specific standards of accuracy and reproducibility. Variances in
proficiency testing schemes indicate a need for accuracy and analytical
standardisation. Standardisation would mean that analytical measures are directly
comparable to each other. Specifically, measures would be directly related to NIST
or other similar standards. Measurements then taken at different times would be
direetly related to each other. As clinical care moves into a more distributed model.
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patients will receive their care through networks of medical services. In order to
ensure a transparent continuity of care, it will be necessary to have rationalised
reference ranges. A collaborative approach using common protocols for selection of
subjects and sample collection would allow laboratories to share this development.
This has stimulated the Nordic Reference Interval Project (NORIP) in Scandinavia
and the Fukuoka project in Japan.
Ferruccio Ceriotti, the Chair of the IFCC Committee for Reference Intervals and
Decision Limits, in a recent review of Horn and Pesce’s 2005 book on reference
ranges states “while it is a gem of a book and cannot be overlooked by anyone
interested in reference values, it is evident that a single solution for any situation does
not exist”. He expected clearer statements and which way the authors consider the
best to follow (or at least the less dangerous).'^'"
It was not feasible to undertake a complete IFCC or NCCLS recommended medical
and laboratory process for reference interval estimation as it was beyond the scope of
this investigation. Rlood bank samples from the recommended number of subjects,
120 male and 120 female were studied initially.

6.1 The Study of Blood Bank Samples

Results of the 95% non-parametric reference intervals for 120 male blood donors for
21 routine chemistry analytes only agreed with the quoted reference ranges from the
Clinical Biochemistry Cork University Hospital (CUH) in the case of 4 analytes only.
These analytes were amylase, calcium, chloride and urate. In the case of the 120
female blood donors the resulting reference 95% non-parametric reference intervals
for the 21 analytes showed agreement w'ith the CUH quoted reference intervals in 8 of
the ranges. These analytes were ALT, amylase, calcium, chloride, creatinine, HDL,
magnesium and total bilirubin. Outliers were identified and removed and nonparametric reference intervals w'ere re-calculated but because a minimum of 120
subjects are required for a valid reference range, and subject substitution was not
possible in this study, these intervals are not presented.
This work demonstrated the importance of pre-analytical factors such as the length of
venepuncture and the effect of the subject being supine for a considerable period of
time. Results for some subjects would indicate that underlying disease may be
present. Thus, as an exercise in establishing or verifying reference ranges, this body of
work was inappropriate.
112

6.2 Retrospective Study of Patient Data
An alternative approach of observing results in the laboratory database was then
considered. The results of the 95% reference intervals, with 95% confidence intervals,
of the daily means of nineteen analytes, for seventeen groups, in a one-month period
were evaluated. This study yielded plenty of “food for thought”. Information, not
documented previously for this department, included;
i.

demographic information on patient groups

ii.

information on age-based differences.

iii.

information on sex-based differences

In the study of daily means the reason for hospitalisation of a subject was not
computed, fhcrefore, the resulting reference ranges or means for hospitalised groups
would not warrant changes to the quoted CUH reference ranges and would require
further investigation. Sinton’s formula (simple standard normal deviate test) for
deciding whether stratification is neces.sary was applied for each analyte. This meant
that any subgroup with a mean which is > 25% of the range of the total group, or in
this case, the quoted reference range, could warrant a separate range. As the number
“n” for the analytes amylase, gamma glutamyltransferase and iron from GPs was <
120, the resulting reference ranges are not discussed.
The analytes for which groups of CiP patients had means > 25% of the quoted
reference means included:
1. Cholesterol: No GP group had a mean < 25% quoted range hut the quoted
reference range is a mandated “desirable” range, therefore there is no need for change
to the quoted range.
2. Low Density Lipoprotein (LDL): Again, the range quoted is a mandated
“desirable” range and therefore there is no need for change to the quoted reference
range.
3. Potassium: All GP subjects had a mean > 25% of the quoted range mean, all on the
positive side. See below for further discussion on this analyte.
4. Triglycerides: All groups had a mean > 25% of the quoted reference range mean,
but as the fasting status could not be verified, further investigation with known fasting
subjects is required.
5. Urate: The group of female GP subjects over 70 years was the only group of
females to have a mean < 25% of the quoted reference range mean. All others had
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higher mean values, > 25% of the quoted reference range. This poses major questions
of the quoted ranges.
6. Urea: Females over 70 years and ALL male groups from GPs have means > 25%
of the quoted reference range mean. Should the range be totally adjusted upwards or
should just the lower limit be raised? If the lower limit is adjusted upwards alone, the
range will be smaller and then the 25% figure will shrink and means would then ft in.
See below for further discussion on this analyte.
Indeed, far from verifying the quoted reference ranges, this study has generated so
many questions of these ranges that the results will be brought to the CUH
Biochemistry Quality Assurance Group for discussion, deliberation and action in the
near future.
/Vmongst the more notable findings to be brought to the group are:
i.

Albumin: All hospitalised patients yielded reference intervals for albumin that
were below the lower ClJll quoted range of 36g/L. Also, the albumin interval
in every GP group was < 3g/L.
CUH
Quoted R 1

All GP Group
of Studv
g/L '

36-44

40-42

All Hos pitalised
Males
Females
g/L
s/I.
32-35

32-35

Reference Interval in
Tielz Textbook’*’

g/l.
35 -52,
averaging ~3g/L
higher in ambulatory
individuals

The resulting intervals for hospitalised patients certainly indicate that it is
inappropriate to use the quoted reference interval for these individuals.
However, with very ill patients, changes in albumin concentrations are of
more importance than comparison with ambulatoi7 individuals. This study
also found that there was a much higher difference between GP and hospital
patients than the 3g/L quoted in Tietz. One of the factors in this finding may
be the use of Bromocresol Purple in the assay, instead of the more widely used
Bromocresol Green.
11.

AI^P: All samples combined from GPs yielded an ALP reference interval < 9
U/L (84.8 - 93.3U/L). Female groups from GPs had an average ALP range of
10.2 U/L. Male groups from GPs had an average ALP reference interval of
19.2 U/L. The lower limits of the CUH quoted ALP ranges are well below
any found in this study.
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CUH
Quoted R I
U/L
40-130 M
35-110 F

All GP Group
of Study
U/L
85-93

All Hos vitalised
Females
Males
U/L
U/L
102-145
105-138

Reference Interval in
Tietz Textbook'^
U/L
53-128 M
42-98 F

These findings would certainly question the CUH quoted ALP ranges.

iii.

ALT; A result for all GP samples combined was a reference interval of 24.4
32.8 U/L, a range of only 7.4 U/L.
CUH
Quoted R I
U/L
4.0-45.0

All GP Group
of Study
U/L
24.4-32.8

All Hos pitalised
Males
Females
U/L
U/L
29.1-38.4 19.2-30.9

Reference Interval in
Tietz Textbook^^
U/L
13-40 M
10-28 F

The upper limit of the all GP reference interval is well below that of the
quoted reference interval. All male groups had higher values than females.
It is possible that sub-clinical liver damage may have occurred before a
a patient's ALT value appears outside the quoted range. There is speculation
that increased concentrations of ALT, even within the reference interval, may
be a predictor of Non-Alcoholic Fatty Liver Disease (NAFLD). Recent studies
on patients with this disease (diagnosed by ultrasound) found that many
patients had ALT values within the upper reaches of the reference interval.
There may be a degree of insulin resistance in these patients. Liver biopsy
remains the most accurate determination of the histological severity and
prognosis of liver damage.^* Work could be carried out locally on ALT results
from patients with known stages of liver disease, so that early detection in new
patients can be aided. Again questions must be asked about the range quoted.

iv.

Chloride: The combined samples from GPs yielded a chloride range of only
1.4 mmol/L (101.7 - 103.1).
CUH
Quoted R I
mmol/L

All GP Group
of Study
mmol /L

95-107

102-103

All Hos pitalised
Males
Females
mmol /L
mmol /L
10I-I03

102-104

Reference Interval in
Tietz Textbook^^
mmol /L
98-107
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The resulting intervals for all groups were much tighter than those quoted by
the Department or by Tietz. Perhaps the improvement in ISE technology is a
feature here as these intervals have been in existence for many years without
challenge. Again, further questioning of the quoted range is needed.

V.

Cholesterol: The combined samples from GPs yielded a cholesterol range of
only 0.19 ramol/L (5.15 - 5.34 mmol/L). In all age groups, cholesterol was
significantly lower in hospitalised patients, averaging 0.86 mmol/L below
their GP counterparts.

CUH
Quoted R I
mnioJ/L

All GP Group
of Study
mmol /I.

<5.0

5.15-5.34

All Hos pitalised
Males
Females
mmol /L mmol /L
4.00-4.50

4.31-4.65

Reference Interval in
Tietz Textbook^^
mmol /I.
N/A

The All GP group (n=14,051) interval is very interesting. It is suiprisingly
lower than expected. ITiere are two possible explanations for this; (a) the
cholesterol enzymatic reagent is more specific compared to earlier methods
which employed Idebermann-Burchard reagent, and (b) the general population
is responding to dietary and exercise advice. Perhaps it is a combination of
both of these that produced the results seen.

VI.

Creatinine: The combined samples from GPs yielded a creatinine range of
only 7.2 pmol/L (85.8 - 93.0 pmol/L). All creatinine ranges for male GP
samples were broader and values were higher than females of similar age.
Creatinine values are influenced by muscle mass, therefore the differences
between males and females was expected.
CUH
Quoted R I
pmol/L).

All GP Group
of Study
pmol/L).

50-130

86-93.0

All Hos vitalised
Males
Females
pmol/L). (imol/L).
82-206.

85-168

Reference Interval in
Tietz Textbook^^
pmol/L).
62-115 M
53-97 F

As discussed earlier, the Individuality Index for creatinine is very low at 0.33.
This means that the dispersion of values for an individual will span only a
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small part of the reference interval and clinically important results could still
be within the reference interval. Much work is now being carried out on the
estimation of estimated glomerular fdtration rate (e-GFR). The 4~variable
Modification of Diet in Renal Disease Study (MDRD) calculation is used.
This calculation, which incorporates body mass, is proving to very useful in
identifying kidney disease at an early stage, thus benefiting the patient
enormously. The 2005 estimating equation for use with a standardised serum
creatinine assay is GFR=175 x (standardised Scr)'^

x (age)'^^^^ x 0.742 (if

the subject is female) or x 1.212 (if the subject is black. GFR is expressed in
millilitres per minute per 1.73m^, and race is either black or not.
Standardisation of calibration of creatinine assays is very important for this
calculation. Recently a project has been proposed by a colleague within this
department to validate e-GFR calculation. This work will be very valuable.

vii.

Potassium: The combined samples from GPs yielded a potassium reference
interval of 0.45 mmol/L (4.53 — 4.98 mmol/fO.
CIJH
Quoted R 1
mmol/L

All GP Group
of Study
mmol /L

3.5-5.0

4.5-5.0

All Hos pitalised
Males
Females
mmol /L
mmol /L
4.3-4.5

4.2-4.4

Reference Interval in
fietz fextbook^^
mmol /L
3.5-5.1 serum
3.5-4.5 plasma M
3.4-4.4 plasma F

The fact that many of the GP samples arrive several hours or a day after
collection is a factor here, fhc resulting reference intervals for these patients are
in the upper reaches of the quoted reference interval. The comment “Query old
sample” will automatically appear on all of these potassium results. However,
another feature of the findings of this study is that the quoted reference range
spans an area of potassium results not found in any patient group interval results
i.e. 3.5-4.0mmol/L. The quoted reference interval has been in place for a long
time. In recent years there is a preference for the use of clotted samples in the
clinical biochemistry laboratory and perhaps the quoted reference interval
reflected the time when the use of plasma was predominant.
A change in centrifugation practice in the department has occurred since this
study was carried out. The temperature of the centrifuges was increased from
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4^C to 15^C. The major benefit from this practice is that fewer serum samples
have clots causing problems with the analysers. Improved clotting conditions
may also affect the potassium results. Further investigation is required,
viii.

Sodium; The combined samples from GPs yielded a sodium range of only 1.6
mmol/L (138.7 to 140.3 mmol/L).
CUH
Quoted R 1
mmol/L

All GP Group
of Study
mmol /L

132-144

139-140

All Hospitalised
Males
Females
mmol /L
mmol /L
137-139

137-139

Reference Interval in
Tietz Textbook^^
mmol /L
136-145

The striking feature of these results is that all intervals were well within the
quoted reference interval. Hyponatraemic and hypernatraemic patients
constitute a very small percentage of the hospitalised groups but sodium
values in these patients during treatment are monitored frequently, fhe lower
value of the quoted interval would especially warrant questioning.

ix.

Total Bilirubin: The combined samples from GPs yielded a total bilirubin
range of only 1.3 pmol/L (9.7 to 11.0 pmol/L)- Gf the hospitalised female
patients, no group had a reference interval above the CUH quoted range. Of
the hospitalised male patients, only those over the age of 45 had upper limits
of their ranges over the upper CUH quoted range. These were only slightly
over 20 pmol/L, at 24.3pmol/L for the 46 - 70 age-groups and 22.9 pmol/T
for the over 70 year olds.
CUH
Quoted R I
pmol/L).

All GP Group
of Study
pmol/lO-

2.0-20.0

9.7-11.0

All Hospitalised
Males
Females
pmol/L).
pmoI/L).
11.2-19.6

10.1-15.8

Reference Interval in
fietz fextbook^^
pmol/L).
5.0-21.0

A review of the lower end of the quoted interval would seem to be required.
As in the case of ALT, great benefit could be had from establishing local
intervals from patients with known stages of diseases to aid in early detection
in others.

X.

Total Protein: fhe combined samples from GPs yielded a Total Protein
reference interval of only 2.1 g/L (70.2 - 72.3 g/L).
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CUH
Quoted R I
g/L

All GP Group
of Study
g/i.

g/L

g/L

62-82

70-72

64-67

64-67

All Hos pitalised
Males
Females

Reference Interval in
Tietz Textbook'’^
&/ L64-83 ambulatory
60-78 recumbent

The intervals found here were very tight for every group. Those found in
hospitalised patients were close to the lower quoted interval value, which was
expected. The upper interval of the all GP group was surprising, at lOg/L
below the quoted reference range. Serum protein electrophoresis is performed
on samples from subjects where protein abnormalities are suspected. If a
review of the quoted interval was undertaken and a smaller range quoted there
would be an increase in requests for electrophoresis. Again, further questions
need answering.

xi.

Urea: The combined samples from GPs yielded a urea reference interval of
only 0.51 mmol/L (5.64 - 6.15 mmol/L)

Quoted R I
mmol/L

All GP
Group of
Study
mmol /L

2.5-7.0

5.64-6.15

cull

All Hospitalised
.Males
Females
mmol /L
mmol /L
6.68-10.15

6.65-9.03

Reference Interval in
I'ietz Textbook^^
mmol /L
2.9-8.2

Once again, the lower area of the quoted reference interval does not fit in with
those found in GP subjects in this study. However, the primary reason for
requesting urea estimation is to assess kidney function where an increase in
value is indicative of disease. Therefore further investigation on the lower end
of the quoted reference interval would not be as clinically significant as work
on other analytes mentioned already.

The amount of information this study yielded is enormous. With the ever-increasing
volume of assays more valuable information is accumulating on the health and ill
health of a large section of our population. A vast resource of infonnation is available
at this particular laboratory, because it services such a large population from both GP
and hospital clinicians in the Southern area of Ireland. In the case of many of the
analytes the actual range of results from GP patients forms only a small fraction of the
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CUH quoted reference range. Does this mean that our ranges are too broad or are we
screening a very healthy population unnecessarily? It would appear that the ranges
quoted do not stand up to in-depth scrutiny. Patient care may be affected by the
continued use of broad reference ranges, the provenances of which were never
documented. Analytes such as albumin, ALT, calcium, chloride, creatinine, female
HDL cholesterol, potassium, sodium, total bilirubin, total protein, urate and urea will
all be discussed with the Consultant Clinical Biochemist and all senior staff of the
CUH Biochemistry Laboratory’s Quality Assurance Group. Action taken will be
documented.

6.3 Analyte Performance
Analytical pcrfonuance, which impacts on the reference intervals, of each analyte
during the period of the study was satisfactory. All analytes performances were well
within the CldA ’88 legislative targets for total error allow'able. Optimum quality
specifications based on biologieal variation were achieved for ALT, amylase, GOL,
potassium, total bilirubin, triglycerides and urate. Desirable quality specifications
based on biological variation were achieved for albumin, cholesterol, creatinine and
urea. Minimum quality specifications based on biological variation were achieved for
calcium, chloride and total protein, fhe performances of ALP and sodium were
outside the desired quality specifications based on biological variation. In the case of
ALP, the bias was + 12.4%, which is above the desired 9.6%. In the case of Sodium,
the bias was -0.63% which is more than the desirable 0.46%. fhe CVi for ALP is
6.4% and the CV| for Sodium is only 0.7%.
During the period of the study the median Overall Mean Running Variance Index
Score (OMRVLS) in the UKNEQAS for clinical chemistr> was 39, with an average of
OMR VIS of 27 over the previous 12 distributions. The size group 3 encompassed 74
participating laboratories.
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6*4 Conclusions
This project has shown that establishing, or verifying, reference ranges is a verv'
difficult task.
i.

Analysis of samples from healthy individuals who had volunteered to donate
blood, did not achieve the desired outcome of confirming the CUH quoted
reference intervals.

ii.

Studying the daily means of various groups of patients over a one-month
period produced very interesting results and posed many more questions for
the laboratory than answers. The findings of this work will be presented to,
and discussed with, the CUH Biochemistry Quality Assurance Ciroup.

iii.

I he quality and reliability of patient results for routine clinical chemistry
analytes generated by the CUH Biochemistry Laboratory are deemed by
international recommendations to be of a very high standard.

A publication of these results in an easy-to-read leafiet/newslettcr and perhaps a sixmonthly review, similar to this, would be of immense benefit to all users of the
service.

The future lies in developments in information technology which will enhance
electronic patient detail recording. If the Medical Heritage Concept, proposed by
Horn and Pcsce and mentioned earlier, could become a reality then each individual
would have his/her own reference interval based on their history as well as that of
their cohorts and patient care would be greatly improved.
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